US20080314395A1 - Accuracy of Continuous Glucose Sensors - Google Patents

Accuracy of Continuous Glucose Sensors Download PDF

Info

Publication number
US20080314395A1
US20080314395A1 US12/065,257 US6525706A US2008314395A1 US 20080314395 A1 US20080314395 A1 US 20080314395A1 US 6525706 A US6525706 A US 6525706A US 2008314395 A1 US2008314395 A1 US 2008314395A1
Authority
US
United States
Prior art keywords
cgs
calibration
time
value
output
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/065,257
Inventor
Boris P. Kovatchev
Christopher Ryan King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Diabetes Care Inc
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Priority to US12/065,257 priority Critical patent/US20080314395A1/en
Assigned to UNIVERSITY OF VIRGINIA reassignment UNIVERSITY OF VIRGINIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOVATCHEV, BORIS P., KING, CHRISTOPHER RYAN
Publication of US20080314395A1 publication Critical patent/US20080314395A1/en
Assigned to UNIVERSITY OF VIRGINIA PATENT FOUNDATION reassignment UNIVERSITY OF VIRGINIA PATENT FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF VIRGINIA
Assigned to ABBOTT DIABETES CARE, INC. reassignment ABBOTT DIABETES CARE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Assigned to ABBOTT DIABETES CARE INC. reassignment ABBOTT DIABETES CARE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495Calibrating or testing of in-vivo probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7275Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7278Artificial waveform generation or derivation, e.g. synthesising signals from measured signals

Definitions

  • the present invention relates to the art of glucose monitoring, and more particularly to methods and systems for continuous glucose monitoring.
  • BG blood glucose
  • IG interstitial glucose
  • BG and CGS readings arises from following major factors: physiology, sensor calibration, noise, and engineering.
  • the physiological time lag and gradients are changing dynamically with time, with BG levels, and across subjects; and the direct frequent in vivo sampling of IG is extremely difficult. Consequently, the evaluation of engineering performance of CGS is left with a central problem: separating the portion of BG/CGS error due to calibration, sensor noise, and BG/IG gradient.
  • the present invention improves the accuracy and reliability of CGS by improving the calibration of CGS sensors or remedying errors due to physiological time lag or a combination thereof.
  • a method for improving accuracy of a continuous glucose sensor comprises: calibrating the CGS at a first time; and changing the CGS calibration at a second time that is determined based upon a dynamically monitored CGS value, a rate of CGS change, and a predetermined criterion.
  • a method for improving accuracy of a continuous glucose sensor comprises: calibrating the CGS using a first blood glucose data and a second blood glucose data different from the first glucose data.
  • a continuous glucose sensing (CGS) device comprises: first means for measuring interstitial glucose level so as to obtain a CGS output; and a calibration module accessible to the CGS output for improving accuracy of the CGS, further comprising: a monitoring module accessible to the CGS output for dynamically monitoring the CGS and a time derivative of the CGS; and instructing another calibration event based on the dynamic CGS value, the time derivative of the CGS value, and a predetermined criterion.
  • CGS continuous glucose sensing
  • a computer-readable medium having computer executable instructions for performing a method for improving accuracy of a continuous glucose sensor
  • the method comprises: retrieving an initial blood glucose value and a CGS value obtained in a measurement for the initial blood glucose value; monitoring the CGS value and a time derivative of the CGS value over time; determining whether to initiate another calibration based on the monitored CGS values and the time derivative of the CGS value; and calibrating the CGS if it is determined to initiate said another calibration.
  • a computer-readable medium having computer executable instructions for performing a method for improving accuracy of a continuous glucose sensor
  • the method comprises: retrieving a blood glucose value and a CGS value obtained in a measurement for the initial blood glucose value at a first time; and calibrating the CGS at a second time determined by a CGS value at substantially the second time, a time derivative of the CGS, and a predetermined criterion.
  • a system used for treating a disease associated with blood glucose comprises: a continuous glucose device of claim 300 ; means for delivering the CGS values to a disease treating center that is capable of issuing a corresponding treating instruction or taking a corresponding treating action.
  • FIG. 1 schematically illustrates a method for measuring blood glucose levels using a continuous glucose sensor according to an example of the invention
  • FIG. 2 is an exploded diagram showing the continuous glucose sensor comprising a calibrator of FIG. 1 ;
  • FIG. 3 is a gram illustrates functional modules of the calibrator and the time lag corrector according to an example of the invention
  • FIG. 4 a is a block diagram of the calibration module according to an example of the invention.
  • FIG. 4 b is a flow chart of a calibration process according to an example of the invention.
  • FIG. 5 illustrates therein the blood glucose differential during calibration and the accuracy of the CGS improved by an exemplary method of the invention
  • FIG. 6 is a flow chart showing the steps executed for improving the accuracy of the CGS using the time-lag correction method of the invention.
  • FIG. 7 is a flow chart showing the steps executed for calibrating the CGS according to yet another example of the invention.
  • FIG. 8 is a diagram showing the improved CGS measurement using an exemplary method of the invention.
  • FIG. 9 is another diagram showing the improved CGS measurement using an exemplary method of the invention.
  • FIG. 10 is yet another diagram showing the improved CGS measurement using an exemplary method of the invention.
  • FIG. 11 is a flow chart showing the steps executed for improving the accuracy of the CGS according to yet another example of the invention.
  • FIG. 12 is a diagram illustrating a system in which examples of the invention can be implemented.
  • FIG. 13 is a diagram showing an exemplary computing device having computer-readable instructions in which example of the invention can be implemented.
  • This invention provides a method and device for improving accuracy of continuous glucose sensors by improving the calibration of the CGS or by remedying errors arising from the physiological time lag between BG and IG, or a combination thereof.
  • the invention will be discussed in the following with reference to specific examples. However, it will be appreciated by those skilled in the art that the following discussion is for demonstration purposes, and should not be interpreted as a limitation. Other variations without departing from the spirit of the invention are also applicable.
  • CGS 100 detects blood glucose level by measuring the glucose level in interstitial fluid 104 that interacts with blood vessels or arteries; and associating the output value of the CGS to the blood glucose level (the process is often referred to as calibration).
  • This indirect measurement stands on the proven basis that the blood glucose level co-varies with the glucose level in the interstitial fluid.
  • accuracy improver 106 is provided as shown in FIG. 2 .
  • the accuracy improver can improve the accuracy of the CGS by improving the CGS calibration through an optimal calibration recommendation (which will be discussed afterwards), or by remedying the error related to the physiology time lag (which will be discussed afterwards), or by a combination thereof.
  • FIG. 2 shows that the accuracy improver is included in the CGS ( 100 ) as a functional member, it is not required to be so.
  • the accuracy improver can be a stand-alone module or method that is separate from the CGS.
  • the accuracy improver can be implemented in a device in connection to the CGS output for improving the accuracy of the CGS.
  • the accuracy module can be implemented in the form of a sequence of computer-executable codes stored in a computer-readable medium; or can be implemented in hardware of the device, which will be detailed afterwards.
  • FIG. 3 schematically illustrates an exploded view of the accuracy improver ( 106 ) in FIG. 2 .
  • the accuracy improver ( 106 ) comprises CGS calibration module 108 and time lag correction module 110 .
  • the CGS calibration module by performing an optimal calibration recommendation cycle, is designated for improving the calibration of the CGS, thus improving the overall accuracy of the CGS.
  • the time lag correction module ( 110 ) is designated for remedying the error from the physiology time lag between the blood glucose and interstitial glucose levels.
  • the accuracy improver may have only one or both of the CGS calibration and time lag correction modules.
  • FIG. 4 a is a diagram showing functional modules of an exemplary CGS calibration ( 118 ) of FIG. 3 .
  • CGS calibrator 118 comprises initial calibration module 111 , storing module 113 , reassigning module 115 , and decision loop module 117 that further comprises monitoring module 119 , internal request module 121 , self-check initiation module 123 , determining module 125 , and sensor calibration module 129 .
  • the initial calibration module performs initial calibration so as to obtain an initial calibration data pair SG( 0 ) and BG( 0 ) from an initial measurement of BG( 0 ).
  • Storing module 113 couples to the output of the initial calibration module 111 and stores the initial calibration data pair SG( 0 ) and BG( 0 ).
  • Internal request module 121 connects to the output of the monitor module and manages internal requests for calibration.
  • Self-check initiation module 123 is connected to the output of the internal request module and designated for initiating a self-check procedure for optimal calibration timing.
  • determining module 125 makes decisions of whether to perform another calibration by sensor calibration module 129 at the particular time.
  • the calibration data from the calibration after the decision are reassigned to the CGS through reassign module 115 .
  • sensor calibration module 129 can be incorporated into initial sensor calibration module 111 for performing CGS calibration.
  • Any of monitor module 119 , internal request module 121 , self-check module 123 , and determining module 125 can be incorporated into combined functional module(s).
  • FIG. 4 b An exemplary operation of the functional modules in FIG. 4 a so as to accomplish the desired optimal calibration recommendation process of the invention is schematically illustrated in FIG. 4 b .
  • an initial calibration is performed by measuring the blood glucose level BG( 0 ) at the initial time t so as to obtain an initial CGS output SG( 0 ) (step 112 ).
  • This step can be performed by initial calibration module 111 in FIG. 4 a .
  • the initial pair of data BG( 0 ) and SG( 0 ) is recorded at step 114 .
  • This step can be performed by storing module 113 in FIG. 4 a .
  • Such initial calibration can be performed at a time recommended by the CGS manufacture, or at a time determined by the user.
  • the calibration procedure then enters to calibration decision making loop 118 that is administrated by decision loop module 117 as shown in FIG. 4 a.
  • the dynamic monitoring and derivation of the SG′(t) can be performed by monitor module 119 in FIG. 4 a .
  • a self-check procedure for optimal calibration timing is initiated at step 124 . This step triggers the sequence of actions determining whether a calibration should be performed or not performed at this time, e.g. 126 and 128 in FIG. 4 b .
  • the receiving of the calibration request and delivering such request to initiate the self-check procedure can be accomplished by the internal request module 121 in FIG. 4 a ; and the self-check initiation can be accomplished by the self-check initiation module 123 in FIG. 4 a .
  • the internal request for another calibration can be initiated at the time defined by the manufacture, or alternatively, by a time defined by the user, such as a doctor or even proper patients.
  • d(mg/dl) can be 10 mg/dl or higher, such as 15 mg/dl or higher, and more preferably 30 mg/dl or higher.
  • Either one or both of the determinations at steps 126 and 128 can be performed by determination module 125 as shown in FIG. 4 a . If
  • the CGS calibration values are reassigned at step 116 based on the recalibration at step 130 , for example, by respectively replacing the calibration values SG(t 0 ) and BG(t 0 ) with the recalibrated values SG(t 1 ) and BG(t 1 ).
  • the reassigned calibration values are stored at step 114 .
  • the above reassignment can be accomplished by reassigning module 115 in FIG. 4 a.
  • the calibration process After reassigning and recording, the calibration process re-enters the decision making cycle 118 , and repeat the above steps 114 , 120 , 122 , 124 , 126 , 128 , 130 , and 116 .
  • the number of calibration cycles can be determined by the default number of calibrations suggested by the CGS manufacture, or alternatively, by the user. As an example, a plurality of calibration cycles—e.g. 2 to 10, or more typically 3 to 4 calibration cycles can be performed during the first 24 hours of CGS life.
  • T1DM type 1 diabetes mellitus
  • GCRC general clinic research center
  • a Minimed CGMSTM was attached to each subject and was calibrated during the study in accordance with the manufacturer's instructions. All CGMSTM were inserted in the abdomen. Hyperinsulmemic clamps were performed in the morning. Each clamp used constant insulin infusion rate of 1 mU/kg/min and variable glucose infusion rate to achieve and maintain BG levels at approximately 110 mg/dl (around 6 mmol/l).
  • the glucose infusion rate was reduced to permit a controlled decline in BG of approximately 1 mg/dl/min until BG reached 50 mg/dl (around 2.8 mmol/l).
  • Glucose infusion was then resumed to allow a recovery to normal glucose levels.
  • the euglycemic portion of the clamp study varied in length from 70 to 210 minutes; and the duration of the BG reduction procedure ranged from 30 to 60 minutes. The recovery ranged from 30 to 60 minutes.
  • Arterialized blood was achieved by warming the hand to 50° C. and was sampled every 5 minutes for reference BG levels. To allow for insulin to reach its steady state effect, the first 15 minutes of data after the beginning of infusion were ignored.
  • CGMSTM readings were synchronized with reference BG.
  • a recalibration of the sensor using 2 reference BG values taken during the clamp study described above is computer-simulated, as shown in FIG. 5 that presents the sensor error as a function of the difference between the two BG values.
  • the simulated recalibration uses the standard linear calibration function of the CGMSTM. The results from the recalibration are compared to the sensors' own accuracy displayed during the experiment and to a “perfect” calibration using all available reference BG values.
  • the X-axis presents the distance between two simulated calibration points in BG units (mg/dl); and the Y-axis presents the mean absolute error (MAE) of the sensor output with the two-point calibration.
  • MAE mean absolute error
  • physiology time lag between BG and IG also causes inaccuracy in the CGS output. This arises from the fact that most of current CGS devices doe not directly measure the blood glucose levels, but the IG levels in the interstitial fluids instead. CGS devices then convert the IG readings into estimates of BG. Therefore, an improved conversion method from IG to BG will lead to improved performance of CGS.
  • An object of the invention improves the conversion from IG to BG by including the physiology time lag between the IG and BG levels. Such improvement is accomplished through analyses and incorporation of the time dependency between IG and BG. Specifically, a mathematical model is established for describing the time dependency among BG and IG or CGS output.
  • a mathematical equation is derived to quantitatively express the time dependence of CGS output on BG—that is CGS is a function of BG. This equation is then converted so as to express BG as a function of CGS.
  • the inverted equation can thus be used to predict the BG level for given CGS output values.
  • the inverted equation is applied to the raw CGS data to produce accurate BG estimates.
  • glucose is a relatively small molecule
  • glucose can diffuse freely through capillary wall, such as blood vessels and adipose tissues.
  • Adipose tissue is highly vascularized; and the interstitial fluid occupies a relatively thin layer between cells. This fact implies that there is no volume element that is very far from a cell surface, nor is it very far from a capillary wall. Therefore, uptake and diffusion of glucose in the interstitial fluid can be assumed to be relatively topologically uniform.
  • FIG. 1 The transportation behavior of the IG and BG according to the invention is depicted in FIG. 1 .
  • the transport behavior of glucose between interstitial fluid and blood vessels (or adipose tissues) can be modeled as diffusion.
  • IG in the interstitial fluid also experiences consumption, which results in amount and/or concentration reduction.
  • is the uptake of glucose per unit time per unit volume.
  • equations 1a and 1b describe the explicit time dependence.
  • Other variables such as insulin levels, exercise, and the like, which may directly effect the glucose uptake BG and IG, are not excluded from the equations.
  • Km is a constant in equation 1b; and it does not introduce additional fitable parameters.
  • Km can take those published values for the activity of GLUI-4, asset forth in “ Whole body glucose metabolism” by Zierler K, in Am J Physiol. 276:E409-E426, 1999, the subject matter of which is incorporated herein by reference in entirety.
  • Fick's Law the change in IG(t) due to diffusion from the blood can be described by equation 2:
  • equations 1a and 1b which can be expressed as the following equations 3a and 3b, wherein equation 3a corresponds to the uniform uptake diffusion model, and equation 3b corresponds to the Michaelis-Menten kinetic model.
  • Equation 3a is an ordinary differential equation that has analytical solutions; while equation 3b is a non-linear differential equation of the second type Abel equation that requires numerical simulation.
  • the analytical solution for equation 3a is expressed in the following equation 4:
  • equation 4 can be reduced to the following equation 6 using the Delta-tau notation as presented in the following equation 5:
  • equation 6 By removing the higher order derivative terms of BG(t) in equation 6, equation 6 can then be reduced to a form to which a Kalman recursion analysis based on Kalman filtering/smoothing technique are applicable.
  • An exemplary of such technique is set forth in “ Optimal Control and Estimation” New York: Dover Publications, 1994 37, the subject matter of which is incorporated herein by reference in entirety, wherein a “state-space model” and recursion process are used. The recursion process is attached herein in Appendix B.
  • a state-space model for dependence of CGS output and IG can be described in the following equation 9.
  • a state-space model for CGS output including the BG evolution can be expressed as the following equation 10.
  • a state-space model for CGS output including the BG evolution and linear projection can be expressed as the following equation 11.
  • equations 3a and 3b can be similarly performed given the estimates of consumption, permeability, IG, and the rate of change of IG.
  • the inversed equations of 3a and 3b are respectively presented as the following equations 12a and 12b:
  • Equations 12a and 12b indicate that the use of CGS becomes important to provide accurate estimates of the rate of change of IG. Presentations of the inversed equations 12a and 12b are also possible, which are expressed as following equations 13 and 14.
  • the mathematical model as discussed above is developed at step 132 .
  • the model describes the dynamics among BG(t), IG(t), and CGS output SG(t).
  • the first mathematical equation is reduced so as to find out SG(t) as a function of BG(t).
  • This first equation is preferably developed using Fick's law of diffusion and Michaelis-Menten consumption.
  • the first equation is then inversed so as to estimate the dynamics of BG(t) as a function of CGS output SG(t) at step 136 .
  • the inversed equation can then be applied to the CGS raw data to improve the accuracy of the CGS readings at step 138 .
  • An exemplary application of the inversed equation to the raw CGS data at step 138 is illustrated in FIG. 7 .
  • the data sets comprise CGS outputs SG(t i ), sample time Tm(t i ), and parameters Par ( ⁇ , ⁇ , calib), wherein parameter calib is a parameter presented in equation 9 as calibration.
  • the raw CGS data are preferably preprocessed (though not required) at step 142 .
  • the CGS raw data are processed by initial regression and/or filtering to smooth CGS raw data. This step is important in that the investigation showed that the raw CGS data current suffer from noise and random spikes that need to be filtered out in order to improve the accuracy of the inverted model equation. There are many ways to regress and/or filter the CGS data.
  • the raw CGS data can be filtered based upon clinically observed BG rate-of-change in combination with a Bayesian estimation technique.
  • the raw CGS output can be processed with a Kalman filter based methods of equations 10 and 11 that produce optimal estimation with the assumption that the evolution of BG meets its limitations.
  • the rate of change (time derivative) of CGS output is calculated at step 144 .
  • a unique feature of the CGS output is the ability to estimate the derivative of their outputs. However, because of the observation and systematic noise and wandering sensor sensitivity, it is observed that such instant raw estimates are rarely optimal. Instead, a short-interval polynomial smoothing technique using exponential weights can produce better results, as indicated by experiments. Then the IG proportionality coefficients are applied to CGS at step 146 , followed by application of the inverted model as described above to estimate the BG level at step 148 .
  • the process as described with reference to FIG. 7 can be implemented in many ways, one of which is in software.
  • the above process can be implemented in a real-time version, which can be of particular usage for the application directly into CGS outputs so as to convert the raw CGS outputs into BG estimates, and produce real-time results.
  • a set of real-time implementation program codes is attached herein as appendix D.
  • the process can be implemented as a retrospective version that is of particular usage for performing retrospective improvement of CGS accuracy; and is applicable to CGS that do not display real-time data.
  • a set of program codes for the retrospective implementation is attached herein as appendix E. It is noted that for ease of reference, the beginning of each line numbers is removed.
  • the hyperinsulinemic clamp used constant insulin infusion rate of 40 mU/kg/min and variable glucose infusion rate to achieve and maintain BG levels at approximately 110 mg/dl. Subsequently, the glucose infusion rate was reduced to permit a controlled decline in BG levels of approximately 1 mg/dl/min until the BG level reached 40 mg/dl.
  • the euglycemic clamp portion of the study varied in length from 70 to 210 minutes, while the duration of the BG reduction procedure ranged from 30 to 60 minutes. Arterialized blood was sampled every 5 minutes and reference BG levels were determined using a Beckman Glucose Analyzer (Beckman Instruments, Inc, Fullerton, Calif.).
  • Freestyle NavigatorTM glucose readings were recorded each minute and were synchronized with reference BG with a precision of 30 seconds. Reference and NavigatorTM rates and direction of BG change were calculated at five-minute intervals. This procedure resulted in 29 clamp data sets for the 16 participants in the study.
  • Equation 12a was applied to the unfiltered NavigatorTM raw data with parameters found via nonlinear least squares. Each data run begins at the start of descent into hypoglycemia. Table 1 presents a summary of the results for all 29 clamp events. It can be seen that the average RMS error of the NavigatorTM was reduced more than 3-folds; and the % RMS error was reduced more that 5-folds. In addition, the correlation between reference and sensor BG was improved by the model:
  • FIG. 8 to FIG. 10 depicts the results. Specifically, FIG. 8 shows the average of the 29 events matched at the nadir with five-minute data intervals.
  • the solid diamond symbols are reference BG recorded by the Beckman analyzer.
  • the solid squares are the data of the NavigatorTM.
  • the open squares are the NavigatorTM corrected by a method of the invention. It can be seen in the figure that the model-corrected data are much closer to reference BG than the original NavigatorTM outputs.
  • FIG. 9 and FIG. 10 show two individual patients with one-minute data interval. In both cases, a correction of the NavigatorTM data by a method of the invention (open squares) results in improved tracing of reference BG.
  • FIG. 11 illustrates a flow chart for performing a combined accuracy improving process in accordance with another example of the invention.
  • the combined process starts from calibrating the CGS using the method as described above with reference to FIG. 4 .
  • System errors can be eliminated or reduced.
  • the CGS outputs from the calibrated CGS are preprocessed at step 152 by filtering and/or smoothing the calibrated CGS output. This step can be performed using the same or different method as described at step 142 in FIG. 7 . It is noted that this step, though preferred, is not required.
  • sensor noise and/or minor random fluctuations in the CGS outputs and the first order time derivative can be removed or reduced.
  • the first order time derivations of CGS outputs SG(t i ) are calculated at step 144 .
  • the IG proportionality coefficient are then applied to the CGS outputs followed by the application of the inverted model equations to estimate the BG level, as described with reference to FIG. 6 , which will not be repeated herein.
  • Table 2 shows the accuracy improvement using the methods according to example of the invention by comparing the CGS outputs obtained from the methods of the invention and the CGS outputs in a typical CGS in the art without employing the methods of the invention.
  • the CGS outputs obtained from the typical CGS in the art are referenced in “Evaluating the accuracy of continuous glucose monitoring sensors: continuous glucose error grid analysis illustrated by therasense freestyle navigator data,” by B Kovatchev, L Gonder Frederick, D Cox, and W Clarke, Diabetes Care , vol. 27, pp 1922-1928, 2004.
  • Panel A of Table 2 presents the continuous glucose error-grid analysis (CG-EGA) of the accuracy of Minimed CGMSTM during the clamp study described above, stratified by hypoglycemia and euglycemia.
  • the clinically accurate sensor readings were 50.0% during hypoglycemia and 96.4% during euglycemia. The large difference between these percentages is primarily due to the more demanding clinical accuracy standards.
  • the sensor is desired to meet higher standards in order to provide accurate feedback for appropriate and timely treatment decision.
  • the CG-EGA reflects this distinction.
  • the MAE and the mean absolute percent error (MAPE) are included in Table 1 and stratified by BG range as well.
  • the panel B in Table 2 presents the CG-EGA, MAE and MAPE of a sensor re-calibrated by two reference BGs that are 30 mg/dl apart (e.g. differential d is 30 mg/dl), which is a clinically reasonable differential in the studied BG range. It can be seen that the percent of CG-EGA accurate readings increases from 50% to 86.7%, while MAE is reduced from 27.9 to 10.9 mg/dl during hypoglycemia. Improvement in MAE and MAPE is observed during euglycemia as well.
  • the panel C of Table 2 presents the CG-EGA, MAE and MAPE of the SIG vs. BG estimated after sensor re-calibration. It can be seen that the “accuracy” of SIG following BG fluctuation is high—nearly 100%, which signifies an excellent theoretical limit for potential sensor accuracy.
  • Examples of the invention can be implemented in many ways. For example, it can be implemented as a functional member of a continuous glucose sensor, or can be implemented as a standalone module associated with the continuous glucose sensor. In either instance, examples of the invention can be implemented as a set of program codes of software installed in a computing device, or a set of computer-executable codes of a hardware device coupled to the continuous glucose sensor. Regardless the implementation media, example of the invention can be associated with individual continuous glucose sensors for improving the accuracy of the individual glucose sensors. Alternatively, examples of the invention can be implemented in such a way that the real-time CGS data, along with related errors and error correction parameters and data, can be transmitted to an error processing center. The transmission may or may not be with the glucose data. In this way, a generalized continuous glucose sensing system can be established.
  • FIG. 12 diagrammatically illustrates an exemplary system in which examples of the invention can be implemented.
  • clinic setup 158 provides a place for doctors (e.g. 164 ) to diagnose patients (e.g. 160 ) with diseases related with glucose.
  • Continuous glucose sensor (or sensing device incorporating glucose testing function) 162 can be used to monitor and/or test the glucose levels of the patient. Such monitor and/or test can be short term (e.g. clinical visit) or long term (e.g. clinical stay or family).
  • the continuous glucose sensor incorporates therein an example of the accuracy improvement methods as discussed above.
  • the CGS outputs with improved accuracy can be used by the doctor for appropriate actions, such as insulin injection or food feeding for the patient, or other appropriate actions.
  • the CGS output with improved accuracy can be delivered to computer terminal 168 for instant or future analyses.
  • the delivery can be through cable or wireless or any other suitable medium.
  • the CGS output with improved accuracy from the patient can also be delivered to a portable device, such as PDA 166 .
  • the CGS outputs with improved accuracy can be delivered to a glucose monitoring center 172 for processing and/or analyzing.
  • Such delivery can be made accomplished through many ways, such as network connection 170 , which can be wired or wireless.
  • examples of the invention can also be implemented in a standalone computing device associated with the target continuous glucose sensors.
  • An exemplary computing device in which examples of the invention can be implemented is schematically illustrated in FIG. 13 . Although such devices are well known to those of skill in the art, a brief explanation will be provided herein for the convenience of other readers.
  • computing device 174 typically includes at least one processing unit 180 and memory 176 .
  • memory 176 can be volatile (such as RAM), non-volatile (such as ROM, flash memory, etc.) or some combination of the two.
  • device 174 may also have other features and/or functionality.
  • the device could also include additional removable and/or non-removable storage including, but not limited to, magnetic or optical disks or tape, as well as writable electrical storage media.
  • additional storage is the figure by removable storage 182 and non-removable storage 178 .
  • Computer storage media includes volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data.
  • the memory, the removable storage and the non-removable storage are all examples of computer storage media.
  • Computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or other memory technology, CDROM, digital versatile disks (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used to store the desired information and which can accessed by the device. Any such computer storage media may be part of, or used in conjunction with, the device.
  • the device may also contain one or more communications connections 184 that allow the device to communicate with other devices (e.g. other computing devices).
  • the communications connections carry information in a communication media.
  • Communication media typically embodies computer readable instructions, data structures, program modules or other data in a modulated data signal such as a carrier wave or other transport mechanism and includes any information delivery media.
  • modulated data signal means a signal that has one or more of its characteristics set or changed in such a manner as to encode information in the signal.
  • communication media includes wired media such as a wired network or direct-wired connection, and wireless media such as acoustic, RF, infrared and other wireless media.
  • the term computer readable media as used herein includes both storage media and communication media.
  • the Kalman filter is a two step process. First, one-step-ahead predictions are made. Second, a correction to that prediction is made based upon new measurements. Let us introduce to notation of ⁇ circumflex over (X) ⁇ i,j meaning “the estimate of x at i given the measurements up to and including j.” Assuming that we have current estimates of x and the error covariance of that estimate, P, we can write the first step as A1.2. In order to correct the estimates, we then calculate the Kalman gain in A1.3, and update the estimates in A1.4 using the new measurement, y.
  • i ⁇ 1 F ⁇ circumflex over (x) ⁇ i ⁇ 1
  • the diagonal operator can be written as in A2.9, which reduces A2.8 to A2.10. Furthermore, by again concatenating the first q+1 column vectors we can form the desired matrix A2.1 in A 2.11.

Abstract

A method, apparatus, and a kit are capable of improving accuracy of CGS devices using dynamic outputs of continuous glucose sensors.

Description

    CROSS-REFERENCE TO RELATED PUBLICATIONS
  • This US patent application claims priority under 35 U.S.C. 119(e) from co-pending U.S. provisional application Ser. No. 60/713,203 filed Aug. 31, 2005, and Ser. No. 60/815,191 filed Jun. 20, 2006, the subject matter of each being incorporated herein by reference in its entirety. The subject matter of each one of the publications and the US provisional application in APPENDIX A attached herewith is incorporated herein by reference in their entirety.
  • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to the art of glucose monitoring, and more particularly to methods and systems for continuous glucose monitoring.
  • BACKGROUND OF THE INVENTION
  • Existing evidence, such as “National Diabetes Fact Sheet” by American Diabetes Association, indicates that currently approximately 18.2 million people in the U.S. have diabetes; and diabetes is the sixth-leading cause of death in the U.S. One in three Americans born in the year 2000 will develop Type 2 diabetes. With the large number of diabetes patients, and with the incidence of diabetes expected to increase, there is a continuously growing need for accurate glucose monitoring systems to monitor glucose levels. Continuous glucose sensors are designed to provide not only real-time glucose levels at a single point in time, but also the trend of a person's glucose levels based on analysis taking place every certain period of time with minimal finger-sticks, leading to improved glycemic/diabetes control.
  • Most contemporary continuous glucose sensors (hereafter CGS), however, yield blood glucose (hereafter BG) estimates by sampling interstitial glucose (hereafter IG) in interstitial fluid, rather than BG due to the difficulty in directly measuring BG in artery or blood vessels. A typical glucose (BG) estimation from IG is produced from at least two consecutive approximation steps: 1) Blood-to-interstitial glucose (BG-to-IG) transport; and 2) Derivation of BG values from IG-related electrical current recorded by the sensor. As a result, although CGS technology has made dramatic strides, the development of accurate and reliable CGS devices continues to face numerous challenges in terms of calibration, sensitivity, stability, and physiological time lag between blood and interstitial glucose concentrations. The difference between BG and CGS readings arises from following major factors: physiology, sensor calibration, noise, and engineering. The physiological time lag and gradients are changing dynamically with time, with BG levels, and across subjects; and the direct frequent in vivo sampling of IG is extremely difficult. Consequently, the evaluation of engineering performance of CGS is left with a central problem: separating the portion of BG/CGS error due to calibration, sensor noise, and BG/IG gradient.
  • Therefore, a method and apparatus are desired for improving accuracy and reliability of CGS.
  • SUMMARY OF THE INVENTION
  • Various objects and advantages of the preferred embodiments of the present invention will be appreciated based on this disclosure. According to the preferred embodiments, the present invention improves the accuracy and reliability of CGS by improving the calibration of CGS sensors or remedying errors due to physiological time lag or a combination thereof.
  • As an exemplary embodiment of the invention, a method for improving accuracy of a continuous glucose sensor (CGS) is disclosed herein. The method comprises: calibrating the CGS at a first time; and changing the CGS calibration at a second time that is determined based upon a dynamically monitored CGS value, a rate of CGS change, and a predetermined criterion.
  • As another exemplary embodiment of the invention, a method for improving accuracy of a continuous glucose sensor (CGS) is disclosed herein. The method comprises: calibrating the CGS using a first blood glucose data and a second blood glucose data different from the first glucose data.
  • As yet another exemplary embodiment of the invention, a continuous glucose sensing (CGS) device is disclosed herein. The device comprises: first means for measuring interstitial glucose level so as to obtain a CGS output; and a calibration module accessible to the CGS output for improving accuracy of the CGS, further comprising: a monitoring module accessible to the CGS output for dynamically monitoring the CGS and a time derivative of the CGS; and instructing another calibration event based on the dynamic CGS value, the time derivative of the CGS value, and a predetermined criterion.
  • As yet another exemplary embodiment of the invention, a computer-readable medium having computer executable instructions for performing a method for improving accuracy of a continuous glucose sensor is disclosed, wherein the method comprises: retrieving an initial blood glucose value and a CGS value obtained in a measurement for the initial blood glucose value; monitoring the CGS value and a time derivative of the CGS value over time; determining whether to initiate another calibration based on the monitored CGS values and the time derivative of the CGS value; and calibrating the CGS if it is determined to initiate said another calibration.
  • As yet another exemplary embodiment of the invention, a computer-readable medium having computer executable instructions for performing a method for improving accuracy of a continuous glucose sensor is disclosed, wherein the method comprises: retrieving a blood glucose value and a CGS value obtained in a measurement for the initial blood glucose value at a first time; and calibrating the CGS at a second time determined by a CGS value at substantially the second time, a time derivative of the CGS, and a predetermined criterion.
  • As yet another exemplary embodiment of the invention, a system used for treating a disease associated with blood glucose is disclosed herein. The system comprises: a continuous glucose device of claim 300; means for delivering the CGS values to a disease treating center that is capable of issuing a corresponding treating instruction or taking a corresponding treating action.
  • Various objects and/or advantages of some preferred embodiments of the invention can be, in some preferred examples, achieved via the features of the independent claims attached hereto. Additional preferred embodiments are further set forth in the dependent claims. In the claims, only elements denoted by the words “means for” are intended to be interpreted as means plus function claims under 35 U.S.C. § 112, the sixth paragraph.
  • BRIEF DESCRIPTION OF DRAWINGS
  • The preferred embodiments of the invention can be best understood from the following detailed description taken in conjunction with the accompanying drawings of which:
  • FIG. 1 schematically illustrates a method for measuring blood glucose levels using a continuous glucose sensor according to an example of the invention;
  • FIG. 2 is an exploded diagram showing the continuous glucose sensor comprising a calibrator of FIG. 1;
  • FIG. 3 is a gram illustrates functional modules of the calibrator and the time lag corrector according to an example of the invention;
  • FIG. 4 a is a block diagram of the calibration module according to an example of the invention;
  • FIG. 4 b is a flow chart of a calibration process according to an example of the invention;
  • FIG. 5 illustrates therein the blood glucose differential during calibration and the accuracy of the CGS improved by an exemplary method of the invention;
  • FIG. 6 is a flow chart showing the steps executed for improving the accuracy of the CGS using the time-lag correction method of the invention;
  • FIG. 7 is a flow chart showing the steps executed for calibrating the CGS according to yet another example of the invention;
  • FIG. 8 is a diagram showing the improved CGS measurement using an exemplary method of the invention;
  • FIG. 9 is another diagram showing the improved CGS measurement using an exemplary method of the invention;
  • FIG. 10 is yet another diagram showing the improved CGS measurement using an exemplary method of the invention;
  • FIG. 11 is a flow chart showing the steps executed for improving the accuracy of the CGS according to yet another example of the invention;
  • FIG. 12 is a diagram illustrating a system in which examples of the invention can be implemented; and
  • FIG. 13 is a diagram showing an exemplary computing device having computer-readable instructions in which example of the invention can be implemented.
  • DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
  • This invention provides a method and device for improving accuracy of continuous glucose sensors by improving the calibration of the CGS or by remedying errors arising from the physiological time lag between BG and IG, or a combination thereof. In view of many possible variations within the spirit of the invention, the invention will be discussed in the following with reference to specific examples. However, it will be appreciated by those skilled in the art that the following discussion is for demonstration purposes, and should not be interpreted as a limitation. Other variations without departing from the spirit of the invention are also applicable.
  • Inaccuracies of most current CGS devices are mainly attributed to poor CGS calibration, physiology time lag, and random errors. To reduce the inaccuracy of the CGS, an improved calibration procedure is proposed. The reduction of inaccuracy can alternatively be achieved by remedying the error related to physiological time lag, which is also proposed in this invention. In fact, the improved calibration procedure and the time lag remedy procedure can alternatively be combined together so as to achieve a better performance of CGS.
  • Referring to FIG. 1, a method of measuring glucose levels in vivo according to an example of the invention is schematically illustrated therein. Because of the large difficulty in directly measuring glucose levels in blood vessels or arteries 102, CGS 100 detects blood glucose level by measuring the glucose level in interstitial fluid 104 that interacts with blood vessels or arteries; and associating the output value of the CGS to the blood glucose level (the process is often referred to as calibration). This indirect measurement stands on the proven basis that the blood glucose level co-varies with the glucose level in the interstitial fluid.
  • To improve the accuracy of CGS, accuracy improver 106 is provided as shown in FIG. 2. The accuracy improver can improve the accuracy of the CGS by improving the CGS calibration through an optimal calibration recommendation (which will be discussed afterwards), or by remedying the error related to the physiology time lag (which will be discussed afterwards), or by a combination thereof. Even though FIG. 2 shows that the accuracy improver is included in the CGS (100) as a functional member, it is not required to be so. In other examples, the accuracy improver can be a stand-alone module or method that is separate from the CGS. Specifically, the accuracy improver can be implemented in a device in connection to the CGS output for improving the accuracy of the CGS. Moreover, the accuracy module can be implemented in the form of a sequence of computer-executable codes stored in a computer-readable medium; or can be implemented in hardware of the device, which will be detailed afterwards.
  • As an example of the invention, FIG. 3 schematically illustrates an exploded view of the accuracy improver (106) in FIG. 2. In this particular example, the accuracy improver (106) comprises CGS calibration module 108 and time lag correction module 110. The CGS calibration module, by performing an optimal calibration recommendation cycle, is designated for improving the calibration of the CGS, thus improving the overall accuracy of the CGS. The time lag correction module (110) is designated for remedying the error from the physiology time lag between the blood glucose and interstitial glucose levels. Depending upon the specific function of the accuracy improver as discussed above, the accuracy improver may have only one or both of the CGS calibration and time lag correction modules.
  • Improved CGS Calibration
  • It is known in the art that the accuracy of CGS calibration depends on the rate of blood glucose (hereafter BG) change and the BG value (BG(t)) at the time (t) of calibration. The rate of BG change can be mathematically expressed as the time derivative of BG(t): d(BG(t))/dt. Given the fact that calibrations with variant inputs are better than those with single or non-varying inputs, the CGS calibration of the invention uses variant inputs.
  • As an example, FIG. 4 a is a diagram showing functional modules of an exemplary CGS calibration (118) of FIG. 3. Referring to FIG. 4 a, CGS calibrator 118 comprises initial calibration module 111, storing module 113, reassigning module 115, and decision loop module 117 that further comprises monitoring module 119, internal request module 121, self-check initiation module 123, determining module 125, and sensor calibration module 129.
  • The initial calibration module performs initial calibration so as to obtain an initial calibration data pair SG(0) and BG(0) from an initial measurement of BG(0). Storing module 113 couples to the output of the initial calibration module 111 and stores the initial calibration data pair SG(0) and BG(0). Monitoring module 119 connects to the output of the storing module and dynamically monitors the CGS output SG(t) and the rate of SG(t) change SG′(t)=dSG(t)/dt. Internal request module 121 connects to the output of the monitor module and manages internal requests for calibration. Self-check initiation module 123 is connected to the output of the internal request module and designated for initiating a self-check procedure for optimal calibration timing. In connection with the output of self-check module 123, determining module 125 makes decisions of whether to perform another calibration by sensor calibration module 129 at the particular time. The calibration data from the calibration after the decision are reassigned to the CGS through reassign module 115.
  • It is noted that one or more above functional modules can be incorporated into other functional modules in practice. In particular, sensor calibration module 129 can be incorporated into initial sensor calibration module 111 for performing CGS calibration. Any of monitor module 119, internal request module 121, self-check module 123, and determining module 125 can be incorporated into combined functional module(s).
  • An exemplary operation of the functional modules in FIG. 4 a so as to accomplish the desired optimal calibration recommendation process of the invention is schematically illustrated in FIG. 4 b. Referring to FIG. 4 b, an initial calibration is performed by measuring the blood glucose level BG(0) at the initial time t so as to obtain an initial CGS output SG(0) (step 112). This step can be performed by initial calibration module 111 in FIG. 4 a. The initial pair of data BG(0) and SG(0) is recorded at step 114. This step can be performed by storing module 113 in FIG. 4 a. Such initial calibration can be performed at a time recommended by the CGS manufacture, or at a time determined by the user. The calibration procedure then enters to calibration decision making loop 118 that is administrated by decision loop module 117 as shown in FIG. 4 a.
  • The calibration decision making loop starts from step 120 that monitors sensor values SG(t) and the rate of change SG′(t) over time with SG′(t) being defined as the first order time derivative of SG(t), that is SG′(t)=dSG(t)/dt. The dynamic monitoring and derivation of the SG′(t) can be performed by monitor module 119 in FIG. 4 a. Upon receiving another calibration request at a specific time t1 (step 122), a self-check procedure for optimal calibration timing is initiated at step 124. This step triggers the sequence of actions determining whether a calibration should be performed or not performed at this time, e.g. 126 and 128 in FIG. 4 b. The receiving of the calibration request and delivering such request to initiate the self-check procedure can be accomplished by the internal request module 121 in FIG. 4 a; and the self-check initiation can be accomplished by the self-check initiation module 123 in FIG. 4 a. It is noted that the internal request for another calibration can be initiated at the time defined by the manufacture, or alternatively, by a time defined by the user, such as a doctor or even proper patients.
  • Following the initiation of the self-check procedure at step 124, it is determined whether |SG′(t1)|<1 at step 126. This determination step can be performed by determination module 125 in FIG. 4 a. If |SG′(t1)≧1, the procedure flows back to step 120 to continuously monitoring the SG(t) and SG′(t) values. Otherwise, the procedure makes another determination of whether |Sg(t1)−SG(t0)| is greater than d(mg/dl), wherein d(mg/dl) is the pre-determined difference threshold between the initial SG(0) and the CGS output at time t1 SG(t1). As an example, d(mg/dl) can be 10 mg/dl or higher, such as 15 mg/dl or higher, and more preferably 30 mg/dl or higher. Either one or both of the determinations at steps 126 and 128 can be performed by determination module 125 as shown in FIG. 4 a. If |Sg(t1)−SG(t0)| is equal to or less than d(mg/dl) at step 128, the procedure flows back to step 120. Otherwise, another calibration is performed at step 130, by for example, sensor calibration module 129 in FIG. 4 a. The CGS calibration values are reassigned at step 116 based on the recalibration at step 130, for example, by respectively replacing the calibration values SG(t0) and BG(t0) with the recalibrated values SG(t1) and BG(t1). The reassigned calibration values are stored at step 114. The above reassignment can be accomplished by reassigning module 115 in FIG. 4 a.
  • After reassigning and recording, the calibration process re-enters the decision making cycle 118, and repeat the above steps 114, 120, 122, 124, 126, 128, 130, and 116. The number of calibration cycles can be determined by the default number of calibrations suggested by the CGS manufacture, or alternatively, by the user. As an example, a plurality of calibration cycles—e.g. 2 to 10, or more typically 3 to 4 calibration cycles can be performed during the first 24 hours of CGS life.
  • The improved accuracy of CGS using the optimal calibration method as discussed above can be validated by the following experimental data and computer-simulations, as shown in FIG. 5.
  • Experimental Data
  • To test the accuracy of the CGS incorporating the accuracy improvement method as discussed above, a measurement is conducted on thirty-nine (39) subjects with type 1 diabetes mellitus (T1DM). The 39 participants have the following statistics: average age 42.5 years with standard deviation (SD) of 12 (SD=12), average duration of T1DM 21.6 years (SD=94), average HbAlc=7.4% (SD=0.8), 16 males.
  • The study was approved by the University of Virginia IRB Subjects. The subjects were admitted to the general clinic research center (GCRC) in the evening prior to the study. The participants' BG levels were controlled overnight within euglycemic range of 100-150 mg/dl (55-8.3 mmol/l). A Minimed CGMS™ was attached to each subject and was calibrated during the study in accordance with the manufacturer's instructions. All CGMS™ were inserted in the abdomen. Hyperinsulmemic clamps were performed in the morning. Each clamp used constant insulin infusion rate of 1 mU/kg/min and variable glucose infusion rate to achieve and maintain BG levels at approximately 110 mg/dl (around 6 mmol/l). Subsequently, the glucose infusion rate was reduced to permit a controlled decline in BG of approximately 1 mg/dl/min until BG reached 50 mg/dl (around 2.8 mmol/l). Glucose infusion was then resumed to allow a recovery to normal glucose levels. The euglycemic portion of the clamp study varied in length from 70 to 210 minutes; and the duration of the BG reduction procedure ranged from 30 to 60 minutes. The recovery ranged from 30 to 60 minutes. Arterialized blood was achieved by warming the hand to 50° C. and was sampled every 5 minutes for reference BG levels. To allow for insulin to reach its steady state effect, the first 15 minutes of data after the beginning of infusion were ignored. CGMS™ readings were synchronized with reference BG.
  • Computer Simulation of Sensor Optimal Calibration
  • A recalibration of the sensor using 2 reference BG values taken during the clamp study described above is computer-simulated, as shown in FIG. 5 that presents the sensor error as a function of the difference between the two BG values. The simulated recalibration uses the standard linear calibration function of the CGMS™. The results from the recalibration are compared to the sensors' own accuracy displayed during the experiment and to a “perfect” calibration using all available reference BG values.
  • Referring to FIG. 5, the X-axis presents the distance between two simulated calibration points in BG units (mg/dl); and the Y-axis presents the mean absolute error (MAE) of the sensor output with the two-point calibration. It can be seen in the figure that MAE is high if the two calibration BGs are close by value. MAE decreases rapidly when the difference approaches 20 mg/dl, and slowly decreases thereafter. The upper horizontal line in the figure represents the MAE of the sensor's own calibration; and the lower horizontal line represents the MAE resulting from a “perfect” calibration using all available reference points.
  • It can also be seen in the figure that the BG calibration difference d with value larger than 30 mg/dl but lower than 40 mg/dl achieves excellent results; whereas the difference d with a value larger than 40 mg/dl achieves “nearly-perfect” results. It is worthwhile to point that the sensor calibration during the experiment described above was always done in periods of steady BG kept at euglycemia, thus the influence of BG rate of change was minimal.
  • Correction of Physiology Time Lag
  • In addition to the calibration of CGS, physiology time lag between BG and IG also causes inaccuracy in the CGS output. This arises from the fact that most of current CGS devices doe not directly measure the blood glucose levels, but the IG levels in the interstitial fluids instead. CGS devices then convert the IG readings into estimates of BG. Therefore, an improved conversion method from IG to BG will lead to improved performance of CGS. An object of the invention improves the conversion from IG to BG by including the physiology time lag between the IG and BG levels. Such improvement is accomplished through analyses and incorporation of the time dependency between IG and BG. Specifically, a mathematical model is established for describing the time dependency among BG and IG or CGS output. Based upon the established model, a mathematical equation is derived to quantitatively express the time dependence of CGS output on BG—that is CGS is a function of BG. This equation is then converted so as to express BG as a function of CGS. The inverted equation can thus be used to predict the BG level for given CGS output values. In application, the inverted equation is applied to the raw CGS data to produce accurate BG estimates.
  • Mathematical Model
  • Given the fact that glucose is a relatively small molecule, it is believed that glucose can diffuse freely through capillary wall, such as blood vessels and adipose tissues. Adipose tissue is highly vascularized; and the interstitial fluid occupies a relatively thin layer between cells. This fact implies that there is no volume element that is very far from a cell surface, nor is it very far from a capillary wall. Therefore, uptake and diffusion of glucose in the interstitial fluid can be assumed to be relatively topologically uniform.
  • The transportation behavior of the IG and BG according to the invention is depicted in FIG. 1. Referring again to FIG. 1, the transport behavior of glucose between interstitial fluid and blood vessels (or adipose tissues) can be modeled as diffusion. IG in the interstitial fluid also experiences consumption, which results in amount and/or concentration reduction.
  • For deriving a mathematical diffusion equation, it is assumed that the particular local interstitial environment in question does not significantly contribute to the development of the BG/time curve, therefore, the time dependence of BG level, BG(t), evolves independently, and can be treated as an exogenous variable in the system. This assumption is particularly safe especially in hyperinsulinemic clamp situations where the BG level is mostly controlled by the IV infusion of dextrose. It is further assumed that the uptake of glucose follows either an IG independent path, or one described by Michaelis-Menten kinetics, as expressed respectively in equations 1a and 1b:
  • I G ( t ) . | UU = I G ( t ) t UU = - α ( t ) Eq . 1 a I G ( t ) . | MM = I G ( t ) t MM = - α ( t ) I G ( t ) Km + I G ( t ) Eq . 1 b
  • In the above equations, α is the uptake of glucose per unit time per unit volume.
  • It is noted that equations 1a and 1b describe the explicit time dependence. Other variables, such as insulin levels, exercise, and the like, which may directly effect the glucose uptake BG and IG, are not excluded from the equations. Km is a constant in equation 1b; and it does not introduce additional fitable parameters. In practice, Km can take those published values for the activity of GLUI-4, asset forth in “Whole body glucose metabolism” by Zierler K, in Am J Physiol. 276:E409-E426, 1999, the subject matter of which is incorporated herein by reference in entirety. By referring to Fick's Law, the change in IG(t) due to diffusion from the blood can be described by equation 2:
  • I G ( t ) . | diffusion = β × [ B G ( t ) - I G ( t ) ] Eq . 2
  • where β is the permeability of the capillary wall to glucose. Since there are no other clear sources or sinks of glucose in the interstitial fluid, the net change of glucose can be derived by adding equations 1a and 1b, which can be expressed as the following equations 3a and 3b, wherein equation 3a corresponds to the uniform uptake diffusion model, and equation 3b corresponds to the Michaelis-Menten kinetic model.
  • I G ( t ) . | net - UU = I G ( t ) t net - UU = β × [ B G ( t ) - I G ( t ) ] - α ( t ) Eq . 3 a I G ( t ) . | net - MM = I G ( t ) t net - MM = β × [ B G ( t ) - I G ( t ) ] - α ( t ) I G ( t ) Km + I G ( t ) Eq . 3 b
  • Mathematical Solutions for Equations 3a and 3b
  • Equation 3a is an ordinary differential equation that has analytical solutions; while equation 3b is a non-linear differential equation of the second type Abel equation that requires numerical simulation. The analytical solution for equation 3a is expressed in the following equation 4:
  • I G ( t ) | net - UU = - β t × [ 0 t [ β × B G ( s ) - α × I G ( ts ) ] st s ] Eq . 4
  • By assuming that α and β are constant over time, equation 4 can be reduced to the following equation 6 using the Delta-tau notation as presented in the following equation 5:
  • Δ τ ( f ( t ) ) f ( t ) - - β ( t - τ ) f ( τ ) Eq . 5 I G ( t ) = I G ( τ ) - β ( t - τ ) + l = 0 ( - 1 β ) l Δ τ ( B G l - α / β ) Eq . 6
  • By removing the higher order derivative terms of BG(t) in equation 6, equation 6 can then be reduced to a form to which a Kalman recursion analysis based on Kalman filtering/smoothing technique are applicable. An exemplary of such technique is set forth in “Optimal Control and Estimation” New York: Dover Publications, 1994 37, the subject matter of which is incorporated herein by reference in entirety, wherein a “state-space model” and recursion process are used. The recursion process is attached herein in Appendix B. Using the “state-space model” and with the assumption that CGS readings are uniformly spaced by a small time ζ, a state-space model for dependence of CGS output and IG can be described in the following equation 9.
  • C G S ( t i ) = calibration × I G ( t i ) + R × w 0 , wherein I G ( t i ) = - β τ × I G ( t i - ξ ) + f ( t i ) + Q × w s ; and wherein f ( t i ) = j = 0 ( - 1 β ) j Δ τ ( B G ( t ) j - α / β ) . Eq . 9
  • A state-space model for CGS output including the BG evolution can be expressed as the following equation 10.
  • B G i + 1 B G . i + 1 B G ¨ i + 1 B G i B G . i B G ¨ i I G i α = [ 1 ɛ 0 0 0 0 0 0 0 1 ɛ 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 - 1 β 1 β 2 - - β ɛ - β ɛ β - β ɛ β 2 - β ɛ - 1 β 0 0 0 0 0 0 0 1 ] × B G i B G . i B G ¨ i B G i - 1 B G . i - 1 B G ¨ i - 1 I G i - 1 α + Q × w s 0 0 ɛ 0 0 . 0 0 0 Equation 10
  • A state-space model for CGS output including the BG evolution and linear projection can be expressed as the following equation 11.
  • [ B G i + 1 B G . i + 1 B G ¨ i + 1 I G i + 1 α ] = [ 1 ɛ 0 0 0 0 1 ɛ 0 0 0 0 1 0 0 β ɛ 0 0 1 - β ɛ - ɛ 0 0 0 0 1 ] × [ B G i B G . i B G ¨ i I G i α ] + Q × w s [ 0 0 ɛ 0 0 ] Eq . 11
  • Inversion of equations 3a and 3b can be similarly performed given the estimates of consumption, permeability, IG, and the rate of change of IG. The inversed equations of 3a and 3b are respectively presented as the following equations 12a and 12b:
  • B G ( t ) = I G ( t ) . + α ( t ) β + I G ( t ) Eq . 12 a B G ( t ) = I G ( t ) . β + I G ( t ) × [ 1 + α / β Km + I G ( t ) ] Eq . 12 b
  • Equations 12a and 12b indicate that the use of CGS becomes important to provide accurate estimates of the rate of change of IG. Presentations of the inversed equations 12a and 12b are also possible, which are expressed as following equations 13 and 14.
  • [ I G ( t i ) I G ( t i - 1 ) C G S ( t i + 1 ) ] = [ 0 0 calib 1 0 0 0 0 0 ] × [ I G ( t i - 1 ) I G ( t i - 2 ) C G S ( t i ) ] + [ 0 0 C G S ( t i + 1 ) ] + Q × w s [ 1 0 0 ] Eq . 13 f ( t i ) = [ 1 - - β ɛ 0 ] × [ I G ( t i ) I G ( t i - 1 ) C G S ( t i + 1 ) ] + R × w 0 Eq . 14
  • It is noted that the observation in the above described model is the function of BG(t) that defined in equation 7. If one accepts a polynomial smoothing/interpolation formula to describe the course of BG(t), then it, too can be linearly inverted, as shown in the attached Appendix C.
  • Algorithmic Implementation
  • The above described mathematical model and equations can then be applied to the CGS readings for remedying the physiology time lag between IG(t) and BG(t) by predicting BG levels using CGS outputs. An exemplary procedure of the invention is presented in the flow chart of FIG. 6.
  • Referring to FIG. 6, the mathematical model as discussed above is developed at step 132. The model describes the dynamics among BG(t), IG(t), and CGS output SG(t). Based upon the model developed at step 132, the first mathematical equation is reduced so as to find out SG(t) as a function of BG(t). This first equation is preferably developed using Fick's law of diffusion and Michaelis-Menten consumption. The first equation is then inversed so as to estimate the dynamics of BG(t) as a function of CGS output SG(t) at step 136. The inversed equation can then be applied to the CGS raw data to improve the accuracy of the CGS readings at step 138. An exemplary application of the inversed equation to the raw CGS data at step 138 is illustrated in FIG. 7.
  • Referring to FIG. 7, sets of raw data are obtained at step 140. The data sets comprise CGS outputs SG(ti), sample time Tm(ti), and parameters Par (α, β, calib), wherein parameter calib is a parameter presented in equation 9 as calibration. The raw CGS data are preferably preprocessed (though not required) at step 142. Specifically, the CGS raw data are processed by initial regression and/or filtering to smooth CGS raw data. This step is important in that the investigation showed that the raw CGS data current suffer from noise and random spikes that need to be filtered out in order to improve the accuracy of the inverted model equation. There are many ways to regress and/or filter the CGS data. For example, the raw CGS data can be filtered based upon clinically observed BG rate-of-change in combination with a Bayesian estimation technique. In another example, the raw CGS output can be processed with a Kalman filter based methods of equations 10 and 11 that produce optimal estimation with the assumption that the evolution of BG meets its limitations.
  • Given the pre-processed CGS data (or directly the raw CGS data without the above pre-processing), the rate of change (time derivative) of CGS output is calculated at step 144. A unique feature of the CGS output is the ability to estimate the derivative of their outputs. However, because of the observation and systematic noise and wandering sensor sensitivity, it is observed that such instant raw estimates are rarely optimal. Instead, a short-interval polynomial smoothing technique using exponential weights can produce better results, as indicated by experiments. Then the IG proportionality coefficients are applied to CGS at step 146, followed by application of the inverted model as described above to estimate the BG level at step 148.
  • Software Implementation
  • The process as described with reference to FIG. 7 can be implemented in many ways, one of which is in software. As an example, the above process can be implemented in a real-time version, which can be of particular usage for the application directly into CGS outputs so as to convert the raw CGS outputs into BG estimates, and produce real-time results. A set of real-time implementation program codes is attached herein as appendix D. Alternatively, the process can be implemented as a retrospective version that is of particular usage for performing retrospective improvement of CGS accuracy; and is applicable to CGS that do not display real-time data. A set of program codes for the retrospective implementation is attached herein as appendix E. It is noted that for ease of reference, the beginning of each line numbers is removed. A linearized version of the parameters is employed in favor of the computation speed. It will be appreciated by those skilled in the art that the program codes presented in appendices D and E are based on for demonstration purposes, and should not be interpreted as a limitation. Many other variations without departing from the spirit of the invention are also applicable.
  • Testing of the Method
  • The above described process for remedying the physiology time lag between BG and CGS output has been evaluated on data acquired during a study performed at the University of Virginia General Clinical Research Center (GCRC), which was an “add-on” project to ongoing NIH research grant (RO1 DK 51562, Principal Investigator Boris Kovatchev). The add-on study was sponsored by Abbott Diabetes Care (P.I. William Clarke) to perform a direct comparison between two CGS: Abbott Navigator™ and Minimed CGMS. The development and testing of the model were among the objectives of the add-on study.
  • Subjects for the Study
  • Sixteen subjects with TIDM (11 male, 5 female, age 42 with standard deviation (SD) of 3 years, duration of diabetes 20 year with SD of 3 years. Informed consent was obtained from each. Subjects were admitted to the General Clinical Research Center in the evening prior to the study following a physical examination. A CGS system, the Freestyle Navigator™ was applied to each subject for approximately 12 hours prior to the initiation of the data recording, in accordance with the manufacturer's instructions and calibrated as recommended. All systems were inserted in the abdomen. No BG reference vs. CGS comparisons was made until the next morning. Study Protocol is defined as that identical hyperinsulinemic clamps were performed on two consecutive days:
  • On each day the hyperinsulinemic clamp used constant insulin infusion rate of 40 mU/kg/min and variable glucose infusion rate to achieve and maintain BG levels at approximately 110 mg/dl. Subsequently, the glucose infusion rate was reduced to permit a controlled decline in BG levels of approximately 1 mg/dl/min until the BG level reached 40 mg/dl. The euglycemic clamp portion of the study varied in length from 70 to 210 minutes, while the duration of the BG reduction procedure ranged from 30 to 60 minutes. Arterialized blood was sampled every 5 minutes and reference BG levels were determined using a Beckman Glucose Analyzer (Beckman Instruments, Inc, Fullerton, Calif.). Freestyle Navigator™ glucose readings were recorded each minute and were synchronized with reference BG with a precision of 30 seconds. Reference and Navigator™ rates and direction of BG change were calculated at five-minute intervals. This procedure resulted in 29 clamp data sets for the 16 participants in the study.
  • Software Used for Analysis
  • Numerical analysis was conducted using R 2.1.1, which is an open-source free programming language and suite for statistic analysis (http//www.r-project.org). Beyond the base packages, the “odesolve,” “fields,” and “dsel” packages and their dependencies from CRAN repositories were used Microsoft Excel was used to produce graphs.
  • Results
  • Equation 12a was applied to the unfiltered Navigator™ raw data with parameters found via nonlinear least squares. Each data run begins at the start of descent into hypoglycemia. Table 1 presents a summary of the results for all 29 clamp events. It can be seen that the average RMS error of the Navigator™ was reduced more than 3-folds; and the % RMS error was reduced more that 5-folds. In addition, the correlation between reference and sensor BG was improved by the model:
  • TABLE 1
    BG prediction using a
    method of the invention Navigator ™
    RMS error (mg/dl) 8.1 27.3
    RMS % error 10.6 55.1
    Pearson Correlation 0.995 0.940
  • FIG. 8 to FIG. 10 depicts the results. Specifically, FIG. 8 shows the average of the 29 events matched at the nadir with five-minute data intervals. The solid diamond symbols are reference BG recorded by the Beckman analyzer. The solid squares are the data of the Navigator™. The open squares are the Navigator™ corrected by a method of the invention. It can be seen in the figure that the model-corrected data are much closer to reference BG than the original Navigator™ outputs. FIG. 9 and FIG. 10 show two individual patients with one-minute data interval. In both cases, a correction of the Navigator™ data by a method of the invention (open squares) results in improved tracing of reference BG.
  • A Combined Accuracy Improvement Method and Device
  • As discussed above, the accuracy of the CGS output can be improved by an example of the invention through an improved calibration method. Alternatively, CGS accuracy can also be improved by remedying the physiology time lag between the BG and IG. In another example of the invention, the above two correction methods can be combined so as to further improve the CGS accuracy. FIG. 11 illustrates a flow chart for performing a combined accuracy improving process in accordance with another example of the invention.
  • Referring to FIG. 11, the combined process starts from calibrating the CGS using the method as described above with reference to FIG. 4. System errors can be eliminated or reduced. The CGS outputs from the calibrated CGS are preprocessed at step 152 by filtering and/or smoothing the calibrated CGS output. This step can be performed using the same or different method as described at step 142 in FIG. 7. It is noted that this step, though preferred, is not required. From the pre-process, sensor noise and/or minor random fluctuations in the CGS outputs and the first order time derivative can be removed or reduced. The first order time derivations of CGS outputs SG(ti) are calculated at step 144. The IG proportionality coefficient are then applied to the CGS outputs followed by the application of the inverted model equations to estimate the BG level, as described with reference to FIG. 6, which will not be repeated herein.
  • Table 2 shows the accuracy improvement using the methods according to example of the invention by comparing the CGS outputs obtained from the methods of the invention and the CGS outputs in a typical CGS in the art without employing the methods of the invention. The CGS outputs obtained from the typical CGS in the art are referenced in “Evaluating the accuracy of continuous glucose monitoring sensors: continuous glucose error grid analysis illustrated by therasense freestyle navigator data,” by B Kovatchev, L Gonder Frederick, D Cox, and W Clarke, Diabetes Care, vol. 27, pp 1922-1928, 2004.
  • TABLE 2
    CG_EGA Accuracy Results
    Accuracy Benign Error MAE MAPE
    Zone % % % mg/dl % N
    Panel A: Original calibration
    Hypoglycemia
    50 0 50 27.9 50.1 376
    Euglycemia 96.4 0.2 3.4 20.4 22.6 532
    Panel B: d = 30 mg/dl calibration
    Hypoglycemia 86.7 4.8 8.5 10.9 19.8 376
    Euglycemia 93.4 2.6 3.9 13.6 14.9 532
    Panel C: BG and SG (CGS output) compensation
    Hypoglycemia
    100 0 0 4.9 8.4 376
    Euglycemia 99.4 0.6 0 7.9 8.4 532
  • Panel A of Table 2 presents the continuous glucose error-grid analysis (CG-EGA) of the accuracy of Minimed CGMS™ during the clamp study described above, stratified by hypoglycemia and euglycemia. The clinically accurate sensor readings were 50.0% during hypoglycemia and 96.4% during euglycemia. The large difference between these percentages is primarily due to the more demanding clinical accuracy standards. For hypoglycemia events: while for steady euglycemic state there is a large clinical tolerance for sensor errors. During clinically dangerous and rapidly developing conditions, such as hypoglycemia, the sensor is desired to meet higher standards in order to provide accurate feedback for appropriate and timely treatment decision. The CG-EGA reflects this distinction. Further, the MAE and the mean absolute percent error (MAPE) are included in Table 1 and stratified by BG range as well.
  • The panel B in Table 2 presents the CG-EGA, MAE and MAPE of a sensor re-calibrated by two reference BGs that are 30 mg/dl apart (e.g. differential d is 30 mg/dl), which is a clinically reasonable differential in the studied BG range. It can be seen that the percent of CG-EGA accurate readings increases from 50% to 86.7%, while MAE is reduced from 27.9 to 10.9 mg/dl during hypoglycemia. Improvement in MAE and MAPE is observed during euglycemia as well.
  • The panel C of Table 2 presents the CG-EGA, MAE and MAPE of the SIG vs. BG estimated after sensor re-calibration. It can be seen that the “accuracy” of SIG following BG fluctuation is high—nearly 100%, which signifies an excellent theoretical limit for potential sensor accuracy.
  • Examples of the invention can be implemented in many ways. For example, it can be implemented as a functional member of a continuous glucose sensor, or can be implemented as a standalone module associated with the continuous glucose sensor. In either instance, examples of the invention can be implemented as a set of program codes of software installed in a computing device, or a set of computer-executable codes of a hardware device coupled to the continuous glucose sensor. Regardless the implementation media, example of the invention can be associated with individual continuous glucose sensors for improving the accuracy of the individual glucose sensors. Alternatively, examples of the invention can be implemented in such a way that the real-time CGS data, along with related errors and error correction parameters and data, can be transmitted to an error processing center. The transmission may or may not be with the glucose data. In this way, a generalized continuous glucose sensing system can be established.
  • FIG. 12 diagrammatically illustrates an exemplary system in which examples of the invention can be implemented. Referring to FIG. 12, clinic setup 158 provides a place for doctors (e.g. 164) to diagnose patients (e.g. 160) with diseases related with glucose. Continuous glucose sensor (or sensing device incorporating glucose testing function) 162 can be used to monitor and/or test the glucose levels of the patient. Such monitor and/or test can be short term (e.g. clinical visit) or long term (e.g. clinical stay or family). The continuous glucose sensor incorporates therein an example of the accuracy improvement methods as discussed above. The CGS outputs with improved accuracy can be used by the doctor for appropriate actions, such as insulin injection or food feeding for the patient, or other appropriate actions. Alternatively, the CGS output with improved accuracy can be delivered to computer terminal 168 for instant or future analyses. The delivery can be through cable or wireless or any other suitable medium. The CGS output with improved accuracy from the patient can also be delivered to a portable device, such as PDA 166. The CGS outputs with improved accuracy can be delivered to a glucose monitoring center 172 for processing and/or analyzing. Such delivery can be made accomplished through many ways, such as network connection 170, which can be wired or wireless.
  • In addition to the CGS outputs with improved accuracy, errors, parameters for accuracy improvements, and any accuracy related information can be delivered, such as to computer 168, and/or data processing center 172 for performing error analyses. This can provide a centralized accuracy monitoring and/or accuracy enhancement for glucose centers, due to the importance of the glucose sensors.\
  • As discussed earlier, examples of the invention can also be implemented in a standalone computing device associated with the target continuous glucose sensors. An exemplary computing device in which examples of the invention can be implemented is schematically illustrated in FIG. 13. Although such devices are well known to those of skill in the art, a brief explanation will be provided herein for the convenience of other readers.
  • Referring to FIG. 13, in its most basic configuration, computing device 174 typically includes at least one processing unit 180 and memory 176. Depending on the exact configuration and type of computing device, memory 176 can be volatile (such as RAM), non-volatile (such as ROM, flash memory, etc.) or some combination of the two.
  • Additionally, device 174 may also have other features and/or functionality. For example, the device could also include additional removable and/or non-removable storage including, but not limited to, magnetic or optical disks or tape, as well as writable electrical storage media. Such additional storage is the figure by removable storage 182 and non-removable storage 178. Computer storage media includes volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. The memory, the removable storage and the non-removable storage are all examples of computer storage media. Computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or other memory technology, CDROM, digital versatile disks (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium which can be used to store the desired information and which can accessed by the device. Any such computer storage media may be part of, or used in conjunction with, the device.
  • The device may also contain one or more communications connections 184 that allow the device to communicate with other devices (e.g. other computing devices). The communications connections carry information in a communication media. Communication media typically embodies computer readable instructions, data structures, program modules or other data in a modulated data signal such as a carrier wave or other transport mechanism and includes any information delivery media. The term “modulated data signal” means a signal that has one or more of its characteristics set or changed in such a manner as to encode information in the signal. By way of example, and not limitation, communication media includes wired media such as a wired network or direct-wired connection, and wireless media such as acoustic, RF, infrared and other wireless media. As discussed above, the term computer readable media as used herein includes both storage media and communication media.
  • It will be appreciated by those of skill in the art that a new and useful method for improving accuracy of continuous glucose sensing devices and system using the same have been discussed herein. In view of the many possible embodiments to which the principles of this invention may be applied, however, it should be recognized that the embodiments described herein with respect to the drawing figures are meant to be illustrative only and should not be taken as limiting the scope of invention. Those of skill in the art will recognize that the illustrated embodiments can be modified in arrangement and detail without departing from the spirit of the invention. Therefore, the invention as described herein contemplates all such embodiments as may come within the scope of the following claims and equivalents thereof.
  • APPENDIX A Subject Matter of the Following Publications and US Provisional Application are Incorporated Herein by Reference in Entirety
    • 1. Santiago J V: Lessons from the Diabetes Control and Complications Trial. Diabetes 1993, 42 1549-1554.
    • 2. B. Feldman, R B˜azgS, Schwartz, and R. Weinstein, “A continuous glucose sensor based on wired enzyme technology and results from a 3 day trial in patients with type 1 diabetes,” Diabetes Technol Ther, vol 5, pp 769-7'78, 2003,
    • 3. D Klonoff, “Continuous glucose monitoring: Roadmap for 21st century diabetes therapy,” Diabetes Care, vol 28, pp 1231-1239, 2005.
    • 4. E Cheyne, D. Cavan, and D. Kerr, “Perfo˜mance of continuous glucose monitoring system during controlled hypoglycemia in healthy volunteers,” Diabetes Technol Ther, vol 4, pp 60'7-613, 2002
    • 5. M Boyne, D Silver, J. Kaplan, and C. Saudek, “Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor;” Diabetes, vol 52, pp 2790-2794, 2003,
    • 6. P T Stout, J R. Racchini, and M. E Hilgers, “A novel approach to mitigating the physiological lag between blood and interstitial fluid glucose measurements,” Diabetes Technol Ther, vol. 6, pp. 635-644, 2004
    • 7. E. Kulcu, J. Tamada, G. Reach, R Potts, and M. Lesho, “Physiological differences between interstitial glucose and blood glucose measured in human subjects,” Diabetes Care, vol 26, pp 2405-2409, 2003,
    • 8. A Schoonen and K Wientjes, “A model for transport of glucose in adipose tissue to a microdialysis probe,” Diabetes Technol Ther, vol. 5, pp. 589-598, 2003
    • 9. G. M Steil, K Rebrin, F Hariri, S Jinagonda, S Tadros, C Darwin, and M F Saad, “Interstitial fluid glucose dynamics during insulin induced hypoglycaemia,” Diabetologia, vol 48, pp. 1833-1840, 2005,
    • 10. K Rebrin and G Steil, “Can interstitial glucose assessment replace blood glucose measurements?” Diabetes Technol Ther, vol. 2, pp. 461472, 2000,
    • 11. Kovatchev, L Gonder Frederick, D Cox, and W Clarke, “Evaluating the accuracy of continuous glucose monitoring sensors: continuous glucose erIor grid analysis illustrated by therasense freestyle navigator data,” Diabetes Care, vol. 27, pp 1922-1928, 2004
    • 12. W Clarke, D. Cox, L Gonder Frederick, W Carter, and S Pohl, “Evaluating clinical accuracy of systems for self-monitoring of blood glucose,” Diabetes Care, vol. 10, pp 622-628.1987,
    • 13. Hanefeld M: Postprandial hyperglycemia: noxious effects on the vessel wall International Journal oj'Clinical Practice, 2002, Supplement 129: 45-50
    • 14. Esposito K, Giugliano D, Nappo F, Martella K, for the Campanian Postprandial Hyperglycemia Study Group. Circulation, 2004, 110: 214-219
    • 15. Quaglim L, Piconi L, Assalone R, Martinelli L, Motz E, Ceriello A: Intermittent I-Iigh Glucose Enhances Apoptosis Related to Oxidative Stress in Human Umbilical Vein Endothelial Cells The Role of protein Kinase C and NAD(P)H-Oxidase Activation Diabetes, 2003, a: 2795-2804.
    • 16. Van der Does F E. De Neeling J N, Snoek F J, Kostense P I, Grootenhuis P A, Bouter L M, and R J Heine: Symptoms and well-being in relation to glycemic control in type I1 diabetes Diabetes Care, 1996, u: 204-210
    • 17. De Sonnaville J J. Snoek F J Colly L P, Deville W. Wijkel D Heine R J: Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care, 1998, a:919-24,
    • 18. Cox D J, Gonder-Frederick L A, McCall A, et al The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hype˜glycaemia among adults with type 1 or type 2 diabetes International Journal ojClinical Practice, 2002, Supplement 129: 20-26
    • 19. Hirsh I B, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J of Diabete˜ and Its Complications, 2005, D: 178-181
    • 20. Reichard P, Phil M Mortality and treatment side effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention study Diabetes 43: 313-317, 1994
    • 21. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus N Engl J Med 329: 978-986, 1993
    • 22. Gross T M, Bode B W, Einhorn D, Kayne D M, Reed I H, White N H, Masttototaro J J: Performance evaluation of the MiMed continuous glucose monitoring system during patient home use Diabetes Technol Thel 2000; 2:49-56
    • 23. Tav˜iDs R, Shoaibi A: The public health impact of the MiniMed Continuous Glucose Monitoring System (CGMSO): an assessment of the literature Diabetes Technol Ther 2004; 6:518-522
    • 24. Chico A, Vidal-Rios P, Subiia M, Novials A: The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control Diabetes Care 26:1153-, 1157, 2003
    • 25. Masbototaro J: The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatt Endocrinol Metab 12:751-758, 1999
    • 26. Feldman B, Brazg R, Schwartz S, Weinstein R: A continuous glucose sensor based on wired enzyme technology—results from a 3-day trial in patients with type 1 diabetes Diabetes Technol Thel 2003; 5(5):769-79
    • 27. Pickup J: Sensitive glucose sensing in diabetes Lancet 355:426-427, 2000
    • 28. Gerzitsen M, Jansen J A, Lutterman J A: Performance of subcutaneously implanted glucose sensors for continuous monitoring Neth J Med 54:167-179, 1999
    • 29. Boyne, Silver, Kaplan, & Saudek: Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor Diabetes 52: 2790-2794, 2003
    • 30. Philip J Stout, Joel R Racchini, Michael E Hilgers: A Novel App˜oachto Mitigating the Physiological Lag Between Blood and Interstitial Fluid Glucose Measurements Diabetes Technol Ther 2004 6:5, 635-644
    • 31. Schoonen & Wientjes: A Model for Transport of Glucose in Adipose Tissue to a Microdialysis Probe Diabetes Technol Ther 2003 5:4,589-59%
    • 32. A S Popel Analysis of capillary-tissue diffusion in multicapillary systems Mathematical Biosciences, 39: 187-211, 19'78,
    • 33. G. M. Steil, K. Rebrin, F Hariri, S Jinagonda, S Tadros, C Darwin and M F Saad, Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia Diabetologia 48:7, published online. DOI: 10.1007/s00125-,005-1852-x
    • 34. Zierler K: Whole body glucose metabolism Am J Physiol 276:E409-E426, 1999
    • 35. Palfreyman R W, Clark A E, Denton R M, Holman G D, Kozka I S: Kinetic resolution of the separate GLUT 1 and GLUT4 glucose transport activities in 3 13-L1 cells Biochem J. 284:275-,282, 1992.
    • 36. Stengel R F: Optimal Control and Estimation New York: Dover Publications, 1994
    • 37. Knobbe E J, Buckingham B: The extended Kalman filter f o c˜ontinuous glucose monitoring Diabetes Technol Ther 2005; 7:15-27,
    • 38. Palerm Cesx C., Willis John P., Desemone James, Bequette B Wayne: Hypoglycemia Prediction and Detection Using Optimal Estimation Diabetes Technol Ther 2005; 7:3-14,
    • 39. “G M. Steil, K Rebrin, F Hariri, S Jinagonda, S Tadros, C Darwin and M F. Saad. Interstitial fluid glucose dynamics du˜ingin sulin-induced hypoglycaemia Diabetologia 48:7, published online. DOI: 101007/s00125-005-1852-x”
    • 40. International Patent Application Serial No. PCTiUS20051013792, entitled “Method, System and Computer. Program Product for Evaluating the Accuracy of Blood Glucose Monitoring SensorsiDevices,” filed Apr. 21, 2005,
    • 41. U.S. provisional application Ser. No. 60/815,191 to Kovatchev et al. filed Jun. 20, 2006;
    APPENDIX B Kalman Recursion Appendix A: Kalman Recursions
  • If we assume that our data follows a system of the form of A1.1, where x is a hidden system state vector, y is an observation vector, ws is system noise with covariance matrix Q, wO is observation noise with covariance matrix R, and the F, G, H matrices define system transitions, then the system is said to be a state space model.

  • x i+1 =Fx i +Gz i +w s

  • y i =Hx i +w o  A1.1)
  • The Kalman filter is a two step process. First, one-step-ahead predictions are made. Second, a correction to that prediction is made based upon new measurements. Let us introduce to notation of {circumflex over (X)}i,j meaning “the estimate of x at i given the measurements up to and including j.” Assuming that we have current estimates of x and the error covariance of that estimate, P, we can write the first step as A1.2. In order to correct the estimates, we then calculate the Kalman gain in A1.3, and update the estimates in A1.4 using the new measurement, y.

  • {circumflex over (x)} i|i−1 =F{circumflex over (x)} i−1|i−1 +G{circumflex over (z)} i−1

  • {circumflex over (P)} i =FP i−1 F T +Q  A1.2)

  • K i ={circumflex over (P)} i H T(H{circumflex over (P)} i H T ÷R)−1  A1.3)

  • {circumflex over (x)} i|i ={circumflex over (x)} i|i−1 +K i(y i −H{circumflex over (x)} i|i−1)

  • P i=(I−K i H){circumflex over (P)} i  A1.4)
  • APPENDIX C Recursion Process
  • X I = B G i , interpj A2 .7 ) diagonal ( X k I ) = B G k ^ A2 .8 )
  • The diagonal operator can be written as in A2.9, which reduces A2.8 to A2.10. Furthermore, by again concatenating the first q+1 column vectors we can form the desired matrix A2.1 in A 2.11.
  • C i { C [ ii ] = 1 , else C [ ij ] = 0 } , diagonal ( A ) = j = 1 n C j Ae j T A2 .9 ) B G k ^ = { i = 1 n C i X k ( X T W i X ) - 1 X T W j } B G , { } M k A2 .10 ) B G ~ = k = 0 q M k B G e k A2 .11 )
  • Finally, by inserting A2.11 into A2.3 we arrive at A 2.12, a linear system which can be solved by methods such as QR decomposition.
  • f ( t ) + α / β = { ( I - δ B S ) k = 0 q M k ( - 1 / β ) k } B G A2 .12 )
  • APPENDIX D Program Codes of Real-Time Implementation Version 1: Real-Time Application:
  • 1 GetNewBGPreds<-function(Nav,times,par) {
    #needs times in minutes to make the parameters work right
    #remove missing values
    2 times[!is,.na(Nav)]->times;Nav[!is.na(Nav)1->Nav;
    #second apply the calibration parameter
  • 3 Navipar [[31]->Nav;
  • #third, create arrays to hold estimates of IG, and dot IG
    4 rep(O., times=length(Nav))->Idot; Nav->IG;
    #fourth, create estimates of dot IG in the time before much data has been collected
    5 (IG[2]-IG[ll)/(times [Z1-times ill)->Idot 121;
    6 #linear interpolation
    7 data frame(y=IG[1:3],x=times[1:31)->td;
    8 lm(y-x,data=td)->tx;t xScoefficients [2]->tx;attr(tx,“names”)<-NULL; tx->Idot [3]
    9 data frame (y=IG[1:4],x=times [1:4])->td;
    10 lm(y-x,data=td)->tx;tx$coefficients [2]->tx;attr (tx, “namesw)<-NULL; tx->Idot [4];
    #fifth, create estimates using splines over the CGS data
    11 for (i in 5:length(Nav)) (
    12 times [(i−4):(i)]->tt;Nav[(i−4):(i) 1->td;
    13 smooth spline(x=tt,y=td,df=1)->temp;
    14 predict (temp,times [i],deriv=1)$ y-2Idot [i];
    15 predict (temp, times [l]) Sy->IG[il;
    16 }
    #sixth, apply the main formula
    17 IG+Idotkpar [[2]]+par [[1]]->NewBG; #seventh, return the result
  • 18 NewBG) APPENDIX E Program Codes of Retrospective Implementation Version 2: Retrospective Correction:
  • In addition to the real-time implementation, one can introduce an artificial delay by extending the time over which each spline is interpolated in line 12 from “(i−4):(i)” to “(i−4):(i+4).” In purely retrospective analysis, one can use the more simple form given next.
  • 19 GetOldBGPreds<-function(Nav,times,par) {
    #eliminate missing values
    20 times [!is .na (Nav)]->times;
  • 21 Nav [!is .na (Nav) 1->Nav;
  • #apply calibration parameter
  • 22 par [[3] 1 *Nav->Nav;
  • #create a smoothing spline regression over all the data
    23 sreg (times, Nav)->Navfit;
    #use it to predict IG
    24 predict (Navfit,times)->IG;
    #use it to predict dot IG
    25 predict(Navfit,times,deriv=1)->Idot;
    #apply main formula
  • 26 (Idot)*par [[2]]+par [[I] 1+IG->BGpreds;
  • #return predictions
  • 27 BGpreds)
  • Finally, if the full Michaelis-Menton form of the equation 3 is desired, then one can simply replaces “par [[1]]” with “par[[1]]*IG/(126.+IG)” in lines 17 and 27. R contains many other smoothing and interpolation facilities, and the use of sreg, smooth spline, and lm can be substituted with many of them, although the input/output format is frequently different.

Claims (53)

1. A method for improving accuracy of a continuous glucose sensor (CGS), comprising:
calibrating the CGS at a first time; and
calibrating the CGS at a second time that is determined based upon at least one of a dynamically monitored CGS value and a rate of CGS change.
2. The method of claim 1, wherein the dynamically monitored CGS value differs by at least 15 mg/dl before the second calibration takes place.
3. The method of claim 1, wherein the dynamically monitored CGS value differs by at least 20 mg/dl before the second calibration takes place.
4. The method of claim 1, wherein the dynamically monitored CGS value differs by at least 30 mg/dl before the second calibration takes place.
5. The method of claim 1, further comprising:
dynamically monitoring the CGS value and the rate of CGS change over time.
6. The method of claim 5, further comprising:
calculating the first order time derivative of the monitored CGS value;
determining whether the absolute value of the first time derivative of the CGS value is substantially less than 1; and
maintaining the calibration of the CGS at the first time when the absolute value of the first time derivative of the CGS value is substantially less than 1.
7. The method of claim 6, further comprising:
determining the absolute change between the CGS at the second time and the CGS at the first time calibration is greater than a pre-determined value when the absolute value of the first time derivative of the CGS value is substantially less than 1; and
maintaining the calibration of the CGS at the first time when the absolute change between the CGS at the second time and the CGS at the first time calibration is greater than a pre-determined value.
8. The method of claim 7, wherein the predetermined value is 30 mg/dl.
9. The method of claim 7, wherein the predetermined value is 40 mg/dl.
10. The method of claim 7, further comprising:
recalibrating the CGS when it is determined that the absolute change between the CGS at the second time and the CGS at the first time calibration is greater than a pre-determined value.
11. The method of claim 1, further comprising:
improving the accuracy of the CGS output by remedying a physiology time lag between the blood glucose level and a glucose level in an interstitial fluid that interacts with the blood glucose.
12. The method of claim 11, wherein the step of improving the accuracy further comprises:
deriving a mathematical equation describing a time dependence of CGS output on the blood glucose level;
deriving the time dependence blood glucose level as a function of the CGS output; and
applying the derived time dependence blood glucose level function to a set of CGS raw outputs so as to predict the blood glucose level at a later time or correcting the CGS output.
13. The method of claim 12, wherein the mathematical equation is derived based on a model that includes a description of a diffusion interaction between the blood glucose and glucose in the interstitial fluid.
14. The method of claim 12, wherein the mathematical equation is derived based on a model that includes a description of an assumption of the glucose in the interstitial fluid.
15. The method of claim 1, wherein the second time that is determined based upon both of the dynamically monitored CGS value and the rate of CGS change.
16. A method for improving the accuracy of a continuous glucose sensor, comprising:
calibrating the continuous glucose sensor using first blood glucose value and second blood glucose value;
measuring the first blood glucose value when the continuous glucose sensor measures a corresponding first interstitial glucose value; and
measuring the second blood glucose value when the continuous glucose sensor measures a corresponding second interstitial glucose value that is different from the first interstitial glucose value by a predetermined amount.
17. The method of claim 16, wherein the predetermined amount is at least 15 mg/dl.
18. The method of claim 16, wherein the predetermined amount is at least 20 mg/dl.
19. The method of claim 17, wherein the first and second glucose data are obtained at different times.
20. The method of claim 17, wherein the second glucose data is obtained through a decision making loop that comprises a determination of a rate of CGS change based on a pre-determined criterion.
21. The method of claim 20, wherein the pre-determined criterion states that if the rate of CGS change is equal to or greater than a pre-determined value, maintaining the CGS calibration with the first glucose data.
22. The method of claim 21, wherein the pre-determined value is 1.
23. The method of claim 22, wherein the pre-determined criterion further states that if the rate of CGS change is less than 1, performing another decision based on another predetermined value.
24. The method of claim 23, wherein said another pre-determined criterion states that if the absolute difference between the CGS and the calibrated CGS with the first blood glucose data is equal to or less than a pre-determined difference value, maintaining the CGS calibration with the first glucose data.
25. The method of claim 24, wherein said another pre-determined criterion further states that if the absolute difference between the CGS and the calibrated CGS with the first blood glucose data is greater than the pre-determined difference value, performing another calibration with the second blood glucose data.
26. The method of claim 17, further comprising:
improving the accuracy of the CGS output by remedying a physiology time lag between the blood glucose level and a glucose level in an interstitial fluid that interacts with the blood glucose.
27. The method of claim 26, wherein the step of improving the accuracy further comprises:
deriving a mathematical equation describing a time dependence of CGS output on the blood glucose level;
deriving the time dependence blood glucose level as a function of the CGS output; and
applying the derived time dependence blood glucose level function to a set of CGS raw outputs so as to correct the CGS output for inherent time lags.
28. The method of claim 27, wherein the mathematical equation is derived based on a model that includes a description of a diffusion interaction between the blood glucose and glucose in the interstitial fluid.
29. The method of claim 27, wherein the mathematical equation is derived based on a model that includes a description of an assumption of the glucose in the interstitial fluid.
30. The method of claim 27, wherein the time dependence blood glucose level as a function of the CGS output is an inversed function of the mathematical equation that describes the time dependence of the CGS output on the blood glucose level.
31. A system for improving an accuracy of a continuous glucose sensor, comprising:
an accuracy improving module accessible to an output of the continuous glucose sensor, further comprising:
a decision making mechanism capable of determining a calibration at a time based upon at least one of a dynamically monitored output of the continuous glucose sensor.
32. The system of claim 31, wherein the decision making mechanism is capable of determining the calibration at the time that is based upon the output of the continuous glucose sensor and a rate of change of the output of the continuous glucose sensor.
33. The system of claim 31, wherein the accuracy improving module further comprises:
an initial request module capable of initiating a calibration at a predetermined time sequence.
34. The system of claim 33, wherein the decision making mechanism further comprises:
a monitoring module capable of dynamically monitoring the output from the continuous glucose sensor.
35. The system of claim 34, wherein the decision making mechanism further comprises:
a determination instruction stating that the dynamically monitored output from the continuous glucose sensor differs by at least 15 mg/dl before the second calibration takes place.
36. The system of claim 34, wherein the decision making mechanism further comprises:
a determination instruction stating that the dynamically monitored output from the continuous glucose sensor differs by at least 20 mg/dl before the second calibration takes place.
37. The system of claim 34, wherein the decision making mechanism further comprises:
a determination instruction stating that the absolute rate of change is substantially equal to or greater than 1 before the second calibration takes place.
38. The system of claim 34, further comprising:
a time lag correction module capable of improving the accuracy of the CGS output by remedying a physiology time lag between the blood glucose level and a glucose level in an interstitial fluid that interacts with the blood glucose.
39. A kit, comprising
a continuous glucose sensor;
a calibration unit in a data communication with to the continuous glucose sensor for calibrating the continuous glucose sensor; and
a set of instructions including instructions for instruction monitoring monitored output from the continuous glucose sensor, and performing first and second calibrations at first and second continuous glucose sensor output values that differ by at least 15 mg/dl.
40. The kit of claim 39, wherein the calibration unit is connectable to the continuous glucose sensor.
41. The kit of claim 39, wherein the calibration unit is an integral member of the continuous glucose sensor.
42. The kit of claim 39, wherein the instruction further states that the dynamically monitored output of the continuous glucose sensor differs by at least 20 mg/dl before the second calibration takes place.
43. The kit of claim 39, wherein the instruction further states that an absolute rate of change of the output of the continuous glucose sensor is less than 1 before the second calibration takes place.
44. The kit of claim 39, wherein the accuracy improving mechanism further comprises:
a time lag correction module accessible to the output of the continuous glucose sensor and capable of remedying a physiology time lag.
45. A method for improving an accuracy of a continuous glucose sensor, comprising:
calibrating the CGS using a first blood glucose level and a second blood glucose level different by a predetermined amount from the first glucose data.
46. The method of claim 45, wherein the predetermined amount is at least 15 mg/dl.
47. The method of claim 46, wherein the predetermined amount is at least 20 mg/dl.
48. The method of claim 47, wherein the second glucose data is obtained through a decision making loop that comprises a determination of a rate of CGS change based on a pre-determined criterion.
49. The method of claim 48, wherein the pre-determined criterion states that if the rate of CGS change is equal to or greater than 1, maintaining the CGS calibration with the first glucose data.
50. A computer-readable medium having computer executable instructions for performing the method set forth in claim 1.
51. A computer-readable medium having computer executable instructions for performing the method set forth in claim 16.
52. A computer-readable medium having computer executable instructions for performing the method set forth in claim 45.
53. A kit, comprising:
a calibration unit for calibrating a continuous glucose, the calibration unit comprising a blood glucose sensor; and
a set of instructions including instructions for monitoring output from a continuous glucose sensor, and performing first and second calibrations at first and second continuous glucose sensor output values that differ by at least 15 mg/dl, where the first and second calibrations comprise respectively first and second determinations of blood glucose with the blood glucose sensor.
US12/065,257 2005-08-31 2006-08-29 Accuracy of Continuous Glucose Sensors Abandoned US20080314395A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/065,257 US20080314395A1 (en) 2005-08-31 2006-08-29 Accuracy of Continuous Glucose Sensors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71320305P 2005-08-31 2005-08-31
US81519106P 2006-06-20 2006-06-20
US12/065,257 US20080314395A1 (en) 2005-08-31 2006-08-29 Accuracy of Continuous Glucose Sensors
PCT/US2006/033724 WO2007027691A1 (en) 2005-08-31 2006-08-29 Improving the accuracy of continuous glucose sensors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033724 A-371-Of-International WO2007027691A1 (en) 2005-08-31 2006-08-29 Improving the accuracy of continuous glucose sensors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/799,329 Continuation US10194850B2 (en) 2005-08-31 2015-07-14 Accuracy of continuous glucose sensors

Publications (1)

Publication Number Publication Date
US20080314395A1 true US20080314395A1 (en) 2008-12-25

Family

ID=37809192

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/065,257 Abandoned US20080314395A1 (en) 2005-08-31 2006-08-29 Accuracy of Continuous Glucose Sensors
US14/799,329 Active 2028-06-04 US10194850B2 (en) 2005-08-31 2015-07-14 Accuracy of continuous glucose sensors
US16/227,910 Pending US20190343433A1 (en) 2005-08-31 2018-12-20 Accuracy of continuous glucose sensors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/799,329 Active 2028-06-04 US10194850B2 (en) 2005-08-31 2015-07-14 Accuracy of continuous glucose sensors
US16/227,910 Pending US20190343433A1 (en) 2005-08-31 2018-12-20 Accuracy of continuous glucose sensors

Country Status (6)

Country Link
US (3) US20080314395A1 (en)
EP (1) EP1921980A4 (en)
JP (2) JP2009507224A (en)
CN (2) CN102440785A (en)
CA (1) CA2620586A1 (en)
WO (1) WO2007027691A1 (en)

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053121A1 (en) * 2007-06-18 2011-03-03 Roche Diagnostics International Ag Method and glucose monitoring system for monitoring individual metabolic response and for generating nutritional feedback
WO2011112974A1 (en) * 2010-03-11 2011-09-15 University Of Virginia Patent Foundation Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
WO2011119832A1 (en) * 2010-03-26 2011-09-29 University Of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
US20120029942A1 (en) * 2009-04-17 2012-02-02 Arkray, Inc. User-Specific Data Provision System, User-Specific Data Provision Method, Server Device, and Handheld Device
US8115635B2 (en) 2005-02-08 2012-02-14 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8216137B2 (en) 2006-10-25 2012-07-10 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2012155032A3 (en) * 2011-05-11 2013-01-10 Bayer Healthcare Llc Back calibration of sensor data
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US8484005B2 (en) 2007-05-14 2013-07-09 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8506482B2 (en) 2006-02-28 2013-08-13 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US8515517B2 (en) 2006-10-02 2013-08-20 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8593109B2 (en) 2006-03-31 2013-11-26 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US8676513B2 (en) 2009-01-29 2014-03-18 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8718739B2 (en) 2008-03-28 2014-05-06 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8718958B2 (en) 2006-10-26 2014-05-06 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8737259B2 (en) 2008-05-30 2014-05-27 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
WO2014128638A1 (en) 2013-02-20 2014-08-28 Università Degli Studi Di Padova Area Trasfermiento Di Tecnologia Retrospective retrofitting method to generate a continuous glucose concentration profile
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9031630B2 (en) 2006-02-28 2015-05-12 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US9088452B2 (en) 2009-04-29 2015-07-21 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US9119529B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2016025874A1 (en) 2014-08-14 2016-02-18 University Of Virginia Patent Foundation Improved accuracy continuous glucose monitoring method, system, and device
US9310230B2 (en) 2009-04-29 2016-04-12 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US9541556B2 (en) 2008-05-30 2017-01-10 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9913600B2 (en) 2007-06-29 2018-03-13 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9931075B2 (en) 2008-05-30 2018-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
WO2018074894A1 (en) * 2016-10-20 2018-04-26 삼성전자 주식회사 Electronic device and method for controlling same
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10173007B2 (en) 2007-10-23 2019-01-08 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US10328201B2 (en) 2008-07-14 2019-06-25 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US10420489B2 (en) 2009-05-29 2019-09-24 University Of Virginia Patent Foundation System coordinator and modular architecture for open-loop and closed-loop control of diabetes
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10685749B2 (en) 2007-12-19 2020-06-16 Abbott Diabetes Care Inc. Insulin delivery apparatuses capable of bluetooth data transmission
EP3068290B1 (en) * 2013-11-14 2020-08-26 The Regents of The University of California Glucose rate increase detector: a meal detection module for the health monitoring system
EP3799073A1 (en) 2011-08-26 2021-03-31 The University of Virginia Patent Foundation Method, system and computer readable medium for adaptive advisory control of diabetes
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11185264B2 (en) * 2017-09-26 2021-11-30 Senseonics, Incorporated Methods and systems for weighting calibration points and updating lag parameters
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US11229382B2 (en) 2013-12-31 2022-01-25 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US11311665B2 (en) 2015-06-09 2022-04-26 University Of Virginia Patent Foundation Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US20220273203A1 (en) * 2007-07-31 2022-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080154513A1 (en) 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
CA2694931C (en) * 2007-07-31 2014-04-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
EP2438152A4 (en) * 2009-06-05 2012-12-12 Glumetrics Inc Algorithms for calibrating an analyte sensor
WO2011105178A1 (en) * 2010-02-26 2011-09-01 アークレイ株式会社 Analysis device, analysis method, and analysis system
WO2017040927A1 (en) 2015-09-02 2017-03-09 University Of Virginia Patent Foundation System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users
US10349872B2 (en) * 2015-12-28 2019-07-16 Medtronic Minimed, Inc. Methods, systems, and devices for sensor fusion
WO2018067348A1 (en) 2016-09-27 2018-04-12 Senseonics, Incorporated Real time modeling of analyte transport concentration
CN108281200A (en) * 2016-12-30 2018-07-13 上海移宇科技股份有限公司 A kind of method of the adjustment algorithm in dynamic blood sugar monitoring system and the dynamic blood sugar monitoring system of application this method
EP4290320A3 (en) 2017-05-05 2024-02-21 Ypsomed AG Closed loop control of physiological glucose
CN108937955A (en) * 2017-05-23 2018-12-07 广州贝塔铁克医疗生物科技有限公司 The adaptive wearable blood glucose bearing calibration of personalization and its means for correcting based on artificial intelligence
JP7216489B2 (en) * 2017-07-04 2023-02-01 アークレイ株式会社 Measuring device, measuring program and measuring method
EP3441829B1 (en) * 2017-08-08 2020-11-11 Siemens Aktiengesellschaft System state prediction
DE202018006591U1 (en) * 2017-08-18 2021-07-21 Abbott Diabetes Care, Inc. Systems and devices relating to the individualized calibration and / or manufacture of medical devices
EP3729446A1 (en) 2017-12-21 2020-10-28 Eli Lilly and Company Closed loop control of physiological glucose
CN110398196A (en) * 2019-07-19 2019-11-01 陕西威尔机电科技有限公司 A kind of LVDT sensor signal processing method and system for accurate measurement
CN114081484B (en) * 2021-11-24 2024-02-27 上海微创生命科技有限公司 Continuous blood glucose detection method, system and readable storage medium
CN114557690B (en) * 2022-02-28 2023-10-13 南京晶捷生物科技有限公司 Calibration system and method for continuous glucose monitoring

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462048A (en) * 1982-02-11 1984-07-24 Rca Corporation Noise reduction circuitry for audio signals
US5568400A (en) * 1989-09-01 1996-10-22 Stark; Edward W. Multiplicative signal correction method and apparatus
US5660163A (en) * 1993-11-19 1997-08-26 Alfred E. Mann Foundation For Scientific Research Glucose sensor assembly
US6143164A (en) * 1997-02-06 2000-11-07 E. Heller & Company Small volume in vitro analyte sensor
US6424847B1 (en) * 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US20030042137A1 (en) * 2001-05-15 2003-03-06 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US20030191377A1 (en) * 2002-04-04 2003-10-09 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US6676816B2 (en) * 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
US20050027181A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20070060803A1 (en) * 2004-02-26 2007-03-15 Liljeryd Lars G Metabolic Monitoring, a Method and Apparatus for Indicating a Health-Related condition of a Subject
US20070118405A1 (en) * 2003-04-18 2007-05-24 Insulet Corporation User Interface For Infusion Pump Remote Controller And Method Of Using The Same
US7258673B2 (en) * 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US20070213657A1 (en) * 2006-02-28 2007-09-13 Abbott Diabetes Care, Inc Smart messages and alerts for an infusion delivery and management system
US7317938B2 (en) * 1999-10-08 2008-01-08 Sensys Medical, Inc. Method of adapting in-vitro models to aid in noninvasive glucose determination
US20080319279A1 (en) * 2007-06-21 2008-12-25 Immersion Corporation Haptic Health Feedback Monitoring
US7499002B2 (en) * 2005-02-08 2009-03-03 International Business Machines Corporation Retractable string interface for stationary and portable devices
US7699964B2 (en) * 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method

Family Cites Families (646)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1191363A (en) 1968-02-19 1970-05-13 Pavelle Ltd Improvements in or relating to Electronic Thermostats.
US3949388A (en) 1972-11-13 1976-04-06 Monitron Industries, Inc. Physiological sensor and transmitter
US3926760A (en) 1973-09-28 1975-12-16 Du Pont Process for electrophoretic deposition of polymer
US4245634A (en) 1975-01-22 1981-01-20 Hospital For Sick Children Artificial beta cell
US3978856A (en) 1975-03-20 1976-09-07 Michel Walter A Heart beat waveform monitoring apparatus
US4036749A (en) 1975-04-30 1977-07-19 Anderson Donald R Purification of saline water
US3960497A (en) 1975-08-19 1976-06-01 Beckman Instruments, Inc. Chemical analyzer with automatic calibration
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4129128A (en) 1977-02-23 1978-12-12 Mcfarlane Richard H Securing device for catheter placement assembly
US4344438A (en) 1978-08-02 1982-08-17 The United States Of America As Represented By The Department Of Health, Education And Welfare Optical sensor of plasma constituents
AU530979B2 (en) 1978-12-07 1983-08-04 Aus. Training Aids Pty. Ltd., Detecting position of bullet fired at target
US4731051A (en) 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
CS210174B1 (en) 1979-07-12 1982-01-29 Ivan Emmer Method of making the electric hygrometric sensor
US4425920A (en) 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4392849A (en) 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
DE3138194A1 (en) 1981-09-25 1983-04-14 Basf Ag, 6700 Ludwigshafen WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE
DE3278334D1 (en) 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US4494950A (en) 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
FI831399L (en) 1982-04-29 1983-10-30 Agripat Sa KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL
EP0098592A3 (en) 1982-07-06 1985-08-21 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
US4509531A (en) 1982-07-28 1985-04-09 Teledyne Industries, Inc. Personal physiological monitor
US4527240A (en) 1982-12-29 1985-07-02 Kvitash Vadim I Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems
US5682884A (en) 1983-05-05 1997-11-04 Medisense, Inc. Strip electrode with screen printing
US5509410A (en) 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
CA1226036A (en) 1983-05-05 1987-08-25 Irving J. Higgins Analytical equipment and sensor electrodes therefor
CA1219040A (en) 1983-05-05 1987-03-10 Elliot V. Plotkin Measurement of enzyme-catalysed reactions
US4538616A (en) 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
DE3429596A1 (en) 1984-08-10 1986-02-20 Siemens AG, 1000 Berlin und 8000 München DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE
CA1254091A (en) 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US5279294A (en) 1985-04-08 1994-01-18 Cascade Medical, Inc. Medical diagnostic system
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4890620A (en) 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4759366A (en) 1986-03-19 1988-07-26 Telectronics N.V. Rate responsive pacing using the ventricular gradient
US4757022A (en) 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US5055171A (en) 1986-10-06 1991-10-08 T And G Corporation Ionic semiconductor materials and applications thereof
US4777953A (en) 1987-02-25 1988-10-18 Ash Medical Systems, Inc. Capillary filtration and collection method for long-term monitoring of blood constituents
US5002054A (en) 1987-02-25 1991-03-26 Ash Medical Systems, Inc. Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
US4854322A (en) 1987-02-25 1989-08-08 Ash Medical Systems, Inc. Capillary filtration and collection device for long-term monitoring of blood constituents
US5365426A (en) 1987-03-13 1994-11-15 The University Of Maryland Advanced signal processing methodology for the detection, localization and quantification of acute myocardial ischemia
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4749985A (en) 1987-04-13 1988-06-07 United States Of America As Represented By The United States Department Of Energy Functional relationship-based alarm processing
EP0290683A3 (en) 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
GB8725936D0 (en) 1987-11-05 1987-12-09 Genetics Int Inc Sensing system
US4925268A (en) 1988-07-25 1990-05-15 Abbott Laboratories Fiber-optic physiological probes
EP0353328A1 (en) 1988-08-03 1990-02-07 Dräger Nederland B.V. A polarographic-amperometric three-electrode sensor
US5340722A (en) 1988-08-24 1994-08-23 Avl Medical Instruments Ag Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method
US5108889A (en) 1988-10-12 1992-04-28 Thorne, Smith, Astill Technologies, Inc. Assay for determining analyte using mercury release followed by detection via interaction with aluminum
US5360404A (en) 1988-12-14 1994-11-01 Inviro Medical Devices Ltd. Needle guard and needle assembly for syringe
US4947845A (en) 1989-01-13 1990-08-14 Pacesetter Infusion, Ltd. Method of maximizing catheter longevity in an implantable medication infusion system
US5068536A (en) 1989-01-19 1991-11-26 Futrex, Inc. Method for providing custom calibration for near infrared instruments for measurement of blood glucose
US5077476A (en) 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
EP0385805B1 (en) 1989-03-03 1996-06-05 Edward W. Stark Signal processing method and apparatus
JPH02298855A (en) 1989-03-20 1990-12-11 Assoc Univ Inc Electrochemical biosensor using immobilized enzyme and redox polymer
US4953552A (en) 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
EP0396788A1 (en) 1989-05-08 1990-11-14 Dräger Nederland B.V. Process and sensor for measuring the glucose content of glucosecontaining fluids
FR2648353B1 (en) 1989-06-16 1992-03-27 Europhor Sa MICRODIALYSIS PROBE
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US4986271A (en) 1989-07-19 1991-01-22 The University Of New Mexico Vivo refillable glucose sensor
US5264105A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5264104A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5320725A (en) 1989-08-02 1994-06-14 E. Heller & Company Electrode and method for the detection of hydrogen peroxide
US5262035A (en) 1989-08-02 1993-11-16 E. Heller And Company Enzyme electrodes
US5050612A (en) 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5082550A (en) 1989-12-11 1992-01-21 The United States Of America As Represented By The Department Of Energy Enzyme electrochemical sensor electrode and method of making it
US5342789A (en) 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
GB2243211A (en) 1990-04-20 1991-10-23 Philips Electronic Associated Analytical instrument and method of calibrating an analytical instrument
US5202261A (en) 1990-07-19 1993-04-13 Miles Inc. Conductive sensors and their use in diagnostic assays
US5113869A (en) 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
ATE106015T1 (en) 1990-09-28 1994-06-15 Pfizer METER DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT.
JP2704672B2 (en) 1990-12-12 1998-01-26 シャーウッド・アイエムエス・インコーポレイテッド Infrared thermometer using calibration mapping
US5148812A (en) 1991-02-20 1992-09-22 Georgetown University Non-invasive dynamic tracking of cardiac vulnerability by analysis of t-wave alternans
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5262305A (en) 1991-03-04 1993-11-16 E. Heller & Company Interferant eliminating biosensors
JPH04278450A (en) 1991-03-04 1992-10-05 Adam Heller Biosensor and method for analyzing subject
US5469855A (en) 1991-03-08 1995-11-28 Exergen Corporation Continuous temperature monitor
US5135004A (en) 1991-03-12 1992-08-04 Incontrol, Inc. Implantable myocardial ischemia monitor and related method
US5204264A (en) 1991-03-14 1993-04-20 E. I. Du Pont De Nemours And Company Method for validation of calibration standards in an automatic chemical analyzer
US5199428A (en) 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5122925A (en) 1991-04-22 1992-06-16 Control Products, Inc. Package for electronic components
US5868711A (en) 1991-04-29 1999-02-09 Board Of Regents, The University Of Texas System Implantable intraosseous device for rapid vascular access
US5328460A (en) 1991-06-21 1994-07-12 Pacesetter Infusion, Ltd. Implantable medication infusion pump including self-contained acoustic fault detection apparatus
CA2074702C (en) 1991-07-29 1996-11-19 Donald J. Urbas Programmable transponder
US5231988A (en) 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
GB9120144D0 (en) 1991-09-20 1991-11-06 Imperial College A dialysis electrode device
US5322063A (en) 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
US5203326A (en) 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5372427A (en) 1991-12-19 1994-12-13 Texas Instruments Incorporated Temperature sensor
US5285792A (en) 1992-01-10 1994-02-15 Physio-Control Corporation System for producing prioritized alarm messages in a medical instrument
US5313953A (en) 1992-01-14 1994-05-24 Incontrol, Inc. Implantable cardiac patient monitor
US5246867A (en) 1992-01-17 1993-09-21 University Of Maryland At Baltimore Determination and quantification of saccharides by luminescence lifetimes and energy transfer
IL104365A0 (en) 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
DE69319771T2 (en) 1992-03-31 1999-04-22 Dainippon Printing Co Ltd Immobilized enzyme electrode, composition for its production and electrically conductive enzymes
EP0636009B1 (en) 1992-04-03 2000-11-29 Micromedical Industries Limited system for physiological monitoring
US5711001A (en) 1992-05-08 1998-01-20 Motorola, Inc. Method and circuit for acquisition by a radio receiver
GB9211402D0 (en) 1992-05-29 1992-07-15 Univ Manchester Sensor devices
DK95792A (en) 1992-07-24 1994-01-25 Radiometer As Sensor for non-invasive, in vivo determination of an analyte and blood flow
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5376070A (en) 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
WO1994010553A1 (en) 1992-10-23 1994-05-11 Optex Biomedical, Inc. Fibre-optic probe for the measurement of fluid parameters
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US5918603A (en) 1994-05-23 1999-07-06 Health Hero Network, Inc. Method for treating medical conditions using a microprocessor-based video game
US5601435A (en) 1994-11-04 1997-02-11 Intercare Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information
US5899855A (en) 1992-11-17 1999-05-04 Health Hero Network, Inc. Modular microprocessor-based health monitoring system
ZA938555B (en) 1992-11-23 1994-08-02 Lilly Co Eli Technique to improve the performance of electrochemical sensors
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
EP0622626B1 (en) 1993-04-23 2002-03-06 Roche Diagnostics GmbH System for analysing the components of fluid samples
US5384547A (en) 1993-08-02 1995-01-24 Motorola, Inc. Apparatus and method for attenuating a multicarrier input signal of a linear device
DE4329898A1 (en) 1993-09-04 1995-04-06 Marcus Dr Besson Wireless medical diagnostic and monitoring device
US5438983A (en) 1993-09-13 1995-08-08 Hewlett-Packard Company Patient alarm detection using trend vector analysis
US5425749A (en) 1993-09-16 1995-06-20 Angeion Corporation Preemptive cardioversion therapy in an implantable cardioverter defibrillator
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5400795A (en) 1993-10-22 1995-03-28 Telectronics Pacing Systems, Inc. Method of classifying heart rhythms by analyzing several morphology defining metrics derived for a patient's QRS complex
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5320715A (en) 1994-01-14 1994-06-14 Lloyd Berg Separation of 1-pentanol from cyclopentanol by extractive distillation
DE4401400A1 (en) 1994-01-19 1995-07-20 Ernst Prof Dr Pfeiffer Method and arrangement for continuously monitoring the concentration of a metabolite
US5543326A (en) 1994-03-04 1996-08-06 Heller; Adam Biosensor including chemically modified enzymes
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5390671A (en) 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5391250A (en) 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5609575A (en) 1994-04-11 1997-03-11 Graseby Medical Limited Infusion pump and method with dose-rate calculation
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
DE4415896A1 (en) 1994-05-05 1995-11-09 Boehringer Mannheim Gmbh Analysis system for monitoring the concentration of an analyte in the blood of a patient
US5472317A (en) 1994-06-03 1995-12-05 Minimed Inc. Mounting clip for a medication infusion pump
US5549115A (en) 1994-09-28 1996-08-27 Heartstream, Inc. Method and apparatus for gathering event data using a removable data storage medium and clock
US5520191A (en) 1994-10-07 1996-05-28 Ortivus Medical Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US6038469A (en) 1994-10-07 2000-03-14 Ortivus Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US5724030A (en) 1994-10-13 1998-03-03 Bio Medic Data Systems, Inc. System monitoring reprogrammable implantable transponder
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5752512A (en) 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US5628310A (en) 1995-05-19 1997-05-13 Joseph R. Lakowicz Method and apparatus to perform trans-cutaneous analyte monitoring
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US7016713B2 (en) 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte
US5628890A (en) 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US5665222A (en) 1995-10-11 1997-09-09 E. Heller & Company Soybean peroxidase electrochemical sensor
US5972199A (en) 1995-10-11 1999-10-26 E. Heller & Company Electrochemical analyte sensors using thermostable peroxidase
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
US5711861A (en) 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
FI960636A (en) 1996-02-12 1997-08-13 Nokia Mobile Phones Ltd A procedure for monitoring the health of a patient
US5785660A (en) 1996-03-28 1998-07-28 Pacesetter, Inc. Methods and apparatus for storing intracardiac electrograms
DE19618597B4 (en) 1996-05-09 2005-07-21 Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm Method for determining the concentration of tissue glucose
US6130602A (en) 1996-05-13 2000-10-10 Micron Technology, Inc. Radio frequency data communications device
US20040249420A1 (en) 1996-05-14 2004-12-09 Medtronic, Inc. Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias
US5735285A (en) 1996-06-04 1998-04-07 Data Critical Corp. Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals
ES2195151T3 (en) 1996-06-18 2003-12-01 Alza Corp IMPROVEMENT OR SAMPLING DEVICE FOR TRANSDERMAL AGENTS.
EP0923335B1 (en) 1996-07-08 2006-08-23 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US5707502A (en) 1996-07-12 1998-01-13 Chiron Diagnostics Corporation Sensors for measuring analyte concentrations and methods of making same
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US5720295A (en) 1996-10-15 1998-02-24 Pacesetter, Inc. Pacemaker with improved detection of atrial fibrillation
US6071249A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US6130623A (en) 1996-12-31 2000-10-10 Lucent Technologies Inc. Encryption for modulated backscatter systems
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US6122351A (en) 1997-01-21 2000-09-19 Med Graph, Inc. Method and system aiding medical diagnosis and treatment
SE9700181D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Ischemia detector and heart stimulator provided with such an ischemia detector
SE9700182D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Implantable heart stimulator
US6293925B1 (en) 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
US6093172A (en) 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
SE9700427D0 (en) 1997-02-07 1997-02-07 Pacesetter Ab Ischemia detector
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
EP1011426A1 (en) 1997-02-26 2000-06-28 Diasense, Inc. Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose
US6159147A (en) 1997-02-28 2000-12-12 Qrs Diagnostics, Llc Personal computer card for collection of real-time biological data
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US6862465B2 (en) 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
US5959529A (en) 1997-03-07 1999-09-28 Kail, Iv; Karl A. Reprogrammable remote sensor monitoring system
US5891047A (en) 1997-03-14 1999-04-06 Cambridge Heart, Inc. Detecting abnormal activation of heart
US5792065A (en) 1997-03-18 1998-08-11 Marquette Medical Systems, Inc. Method and apparatus for determining T-wave marker points during QT dispersion analysis
SE9701122D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Medical implant
SE9701121D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Implantable heart stimulator
US6270455B1 (en) 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US5942979A (en) 1997-04-07 1999-08-24 Luppino; Richard On guard vehicle safety warning system
US5961451A (en) 1997-04-07 1999-10-05 Motorola, Inc. Noninvasive apparatus having a retaining member to retain a removable biosensor
US5935224A (en) 1997-04-24 1999-08-10 Microsoft Corporation Method and apparatus for adaptively coupling an external peripheral device to either a universal serial bus port on a computer or hub or a game port on a computer
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
JP2002505008A (en) 1997-06-16 2002-02-12 エラン コーポレーション ピーエルシー Methods for calibrating and testing sensors for in vivo measurement of analytes and devices for use in such methods
US6731976B2 (en) 1997-09-03 2004-05-04 Medtronic, Inc. Device and method to measure and communicate body parameters
US6764581B1 (en) 1997-09-05 2004-07-20 Abbott Laboratories Electrode with thin working layer
US6071391A (en) 1997-09-12 2000-06-06 Nok Corporation Enzyme electrode structure
US6117290A (en) 1997-09-26 2000-09-12 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US5904671A (en) 1997-10-03 1999-05-18 Navot; Nir Tampon wetness detection system
US6736957B1 (en) 1997-10-16 2004-05-18 Abbott Laboratories Biosensor electrode mediators for regeneration of cofactors and process for using
US6119028A (en) 1997-10-20 2000-09-12 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces
US6088608A (en) 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
FI107080B (en) 1997-10-27 2001-05-31 Nokia Mobile Phones Ltd measuring device
ES2281143T3 (en) 1997-11-12 2007-09-16 Lightouch Medical, Inc. METHOD FOR THE NON-INVASIVE MEASUREMENT OF AN ANALYTE.
CA2547299C (en) 1997-12-04 2009-03-03 Roche Diagnostics Corporation Instrument and method
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US6073031A (en) 1997-12-24 2000-06-06 Nortel Networks Corporation Desktop docking station for use with a wireless telephone handset
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6024699A (en) 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6197181B1 (en) 1998-03-20 2001-03-06 Semitool, Inc. Apparatus and method for electrolytically depositing a metal on a microelectronic workpiece
US6579231B1 (en) 1998-03-27 2003-06-17 Mci Communications Corporation Personal medical monitoring unit and system
JP3104672B2 (en) 1998-03-31 2000-10-30 日本電気株式会社 Current detection type sensor element and method of manufacturing the same
JPH11296598A (en) 1998-04-07 1999-10-29 Seizaburo Arita System and method for predicting blood-sugar level and record medium where same method is recorded
US6091987A (en) 1998-04-29 2000-07-18 Medtronic, Inc. Power consumption reduction in medical devices by employing different supply voltages
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
GB2337122B (en) 1998-05-08 2002-11-13 Medisense Inc Test strip
PT1077636E (en) 1998-05-13 2004-06-30 Cygnus Therapeutic Systems SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION
ATE245937T1 (en) 1998-05-13 2003-08-15 Cygnus Therapeutic Systems MONITORING PHYSIOLOGICAL ANALYTES
US7043287B1 (en) 1998-05-18 2006-05-09 Abbott Laboratories Method for modulating light penetration depth in tissue and diagnostic applications using same
US6121611A (en) 1998-05-20 2000-09-19 Molecular Imaging Corporation Force sensing probe for scanning probe microscopy
AU5394099A (en) 1998-08-07 2000-02-28 Infinite Biomedical Technologies, Incorporated Implantable myocardial ischemia detection, indication and action technology
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6740518B1 (en) 1998-09-17 2004-05-25 Clinical Micro Sensors, Inc. Signal detection techniques for the detection of analytes
US6254586B1 (en) 1998-09-25 2001-07-03 Minimed Inc. Method and kit for supplying a fluid to a subcutaneous placement site
CA2346055C (en) 1998-09-30 2004-06-29 Cygnus, Inc. Method and device for predicting physiological values
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
ATE514372T1 (en) 1998-10-08 2011-07-15 Medtronic Minimed Inc LICENSE PLATE MONITORING SYSTEM WITH REMOTE MEASUREMENT
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6496729B2 (en) 1998-10-28 2002-12-17 Medtronic, Inc. Power consumption reduction in medical devices employing multiple supply voltages and clock frequency control
US6602469B1 (en) 1998-11-09 2003-08-05 Lifestream Technologies, Inc. Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system
DE69924749T2 (en) 1998-11-20 2006-04-27 The University Of Connecticut, Farmington Generically integrated implantable potentiostat remote sensing device for electrochemical probes
US6773671B1 (en) 1998-11-30 2004-08-10 Abbott Laboratories Multichemistry measuring device and test strips
JP4749549B2 (en) 1998-11-30 2011-08-17 アボット・ラボラトリーズ Analytical testing instrument with improved calibration and communication process
JP2002531884A (en) 1998-11-30 2002-09-24 ノボ ノルディスク アクティーゼルスカブ Method and system for assisting a user in self-treatment involving multiple actions
US6161095A (en) 1998-12-16 2000-12-12 Health Hero Network, Inc. Treatment regimen compliance and efficacy with feedback
US7436511B2 (en) 1999-01-22 2008-10-14 Sensys Medical, Inc. Analyte filter method and apparatus
AU3363000A (en) 1999-02-12 2000-08-29 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6112116A (en) 1999-02-22 2000-08-29 Cathco, Inc. Implantable responsive system for sensing and treating acute myocardial infarction
US6360888B1 (en) 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6272379B1 (en) 1999-03-17 2001-08-07 Cathco, Inc. Implantable electronic system with acute myocardial infarction detection and patient warning capabilities
US6128526A (en) 1999-03-29 2000-10-03 Medtronic, Inc. Method for ischemia detection and apparatus for using same
US6115628A (en) 1999-03-29 2000-09-05 Medtronic, Inc. Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals
GB9907815D0 (en) 1999-04-06 1999-06-02 Univ Cambridge Tech Implantable sensor
US6285897B1 (en) 1999-04-07 2001-09-04 Endonetics, Inc. Remote physiological monitoring system
US6416471B1 (en) 1999-04-15 2002-07-09 Nexan Limited Portable remote patient telemonitoring system
US6200265B1 (en) 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6108577A (en) 1999-04-26 2000-08-22 Cardiac Pacemakers, Inc. Method and apparatus for detecting changes in electrocardiogram signals
US6669663B1 (en) 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6359444B1 (en) 1999-05-28 2002-03-19 University Of Kentucky Research Foundation Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
US6423035B1 (en) 1999-06-18 2002-07-23 Animas Corporation Infusion pump with a sealed drive mechanism and improved method of occlusion detection
AU5747100A (en) 1999-06-18 2001-01-09 Therasense, Inc. Mass transport limited in vivo analyte sensor
GB2351153B (en) 1999-06-18 2003-03-26 Abbott Lab Electrochemical sensor for analysis of liquid samples
US6413393B1 (en) 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
US6804558B2 (en) 1999-07-07 2004-10-12 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US6514460B1 (en) 1999-07-28 2003-02-04 Abbott Laboratories Luminous glucose monitoring device
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6923763B1 (en) 1999-08-23 2005-08-02 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US6343225B1 (en) 1999-09-14 2002-01-29 Implanted Biosystems, Inc. Implantable glucose sensor
AT408182B (en) 1999-09-17 2001-09-25 Schaupp Lukas Dipl Ing Dr Tech DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS
EP1217942A1 (en) 1999-09-24 2002-07-03 Healthetech, Inc. Physiological monitor and associated computation, display and communication unit
US6294997B1 (en) 1999-10-04 2001-09-25 Intermec Ip Corp. RFID tag having timing and environment modules
US6478736B1 (en) 1999-10-08 2002-11-12 Healthetech, Inc. Integrated calorie management system
US6249705B1 (en) 1999-10-21 2001-06-19 Pacesetter, Inc. Distributed network system for use with implantable medical devices
US20060091006A1 (en) 1999-11-04 2006-05-04 Yi Wang Analyte sensor with insertion monitor, and methods
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
DK1230249T3 (en) 1999-11-15 2004-08-30 Therasense Inc Transition metal complexes with bidentate ligand having an imidazole ring
US6291200B1 (en) 1999-11-17 2001-09-18 Agentase, Llc Enzyme-containing polymeric sensors
US6658396B1 (en) 1999-11-29 2003-12-02 Tang Sharon S Neural network drug dosage estimation
US6418346B1 (en) 1999-12-14 2002-07-09 Medtronic, Inc. Apparatus and method for remote therapy and diagnosis in medical devices via interface systems
US7060031B2 (en) 1999-12-17 2006-06-13 Medtronic, Inc. Method and apparatus for remotely programming implantable medical devices
US6497655B1 (en) 1999-12-17 2002-12-24 Medtronic, Inc. Virtual remote monitor, alert, diagnostics and programming for implantable medical device systems
US6377852B1 (en) 2000-01-20 2002-04-23 Pacesetter, Inc. Implanatable cardiac stimulation device and method for prolonging atrial refractoriness
US7369635B2 (en) 2000-01-21 2008-05-06 Medtronic Minimed, Inc. Rapid discrimination preambles and methods for using the same
US6974437B2 (en) 2000-01-21 2005-12-13 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
WO2001052935A1 (en) 2000-01-21 2001-07-26 Medical Research Group, Inc. Ambulatory medical apparatus and method having telemetry modifiable control software
DK1248660T3 (en) 2000-01-21 2012-07-23 Medtronic Minimed Inc Microprocessor controlled outpatient medical device with handheld communication device
US7003336B2 (en) 2000-02-10 2006-02-21 Medtronic Minimed, Inc. Analyte sensor method of making the same
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US7890295B2 (en) 2000-02-23 2011-02-15 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6572542B1 (en) 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6405066B1 (en) 2000-03-17 2002-06-11 The Regents Of The University Of California Implantable analyte sensor
EP1267708A4 (en) 2000-03-29 2006-04-12 Univ Virginia Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US6610012B2 (en) 2000-04-10 2003-08-26 Healthetech, Inc. System and method for remote pregnancy monitoring
US6561975B1 (en) 2000-04-19 2003-05-13 Medtronic, Inc. Method and apparatus for communicating with medical device systems
US6440068B1 (en) 2000-04-28 2002-08-27 International Business Machines Corporation Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device
AU2001263022A1 (en) 2000-05-12 2001-11-26 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
US7181261B2 (en) 2000-05-15 2007-02-20 Silver James H Implantable, retrievable, thrombus minimizing sensors
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US6361503B1 (en) 2000-06-26 2002-03-26 Mediwave Star Technology, Inc. Method and system for evaluating cardiac ischemia
US6540675B2 (en) 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US6400974B1 (en) 2000-06-29 2002-06-04 Sensors For Medicine And Science, Inc. Implanted sensor processing system and method for processing implanted sensor output
CA2408338C (en) 2000-08-18 2009-09-08 Cygnus, Inc. Methods and devices for prediction of hypoglycemic events
WO2002017210A2 (en) 2000-08-18 2002-02-28 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
EP1311189A4 (en) 2000-08-21 2005-03-09 Euro Celtique Sa Near infrared blood glucose monitoring system
US7226442B2 (en) 2000-10-10 2007-06-05 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
DE60139411D1 (en) 2000-10-26 2009-09-10 Medtronic Inc DEVICE FOR MINIMIZING THE EFFECTS OF A HEART INJURY
US6695860B1 (en) 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
US6574510B2 (en) 2000-11-30 2003-06-03 Cardiac Pacemakers, Inc. Telemetry apparatus and method for an implantable medical device
US7052483B2 (en) 2000-12-19 2006-05-30 Animas Corporation Transcutaneous inserter for low-profile infusion sets
US6490479B2 (en) 2000-12-28 2002-12-03 Ge Medical Systems Information Technologies, Inc. Atrial fibrillation detection method and apparatus
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6970529B2 (en) 2001-01-16 2005-11-29 International Business Machines Corporation Unified digital architecture
US20040197846A1 (en) 2001-01-18 2004-10-07 Linda Hockersmith Determination of glucose sensitivity and a method to manipulate blood glucose concentration
MXPA03006421A (en) 2001-01-22 2004-12-02 Hoffmann La Roche Lancet device having capillary action.
EP1384193A2 (en) 2001-03-14 2004-01-28 Baxter International Inc. Internet based therapy management system
US6968294B2 (en) 2001-03-15 2005-11-22 Koninklijke Philips Electronics N.V. Automatic system for monitoring person requiring care and his/her caretaker
US6622045B2 (en) 2001-03-29 2003-09-16 Pacesetter, Inc. System and method for remote programming of implantable cardiac stimulation devices
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US7916013B2 (en) 2005-03-21 2011-03-29 Greatbatch Ltd. RFID detection and identification system for implantable medical devices
GR1003802B (en) 2001-04-17 2002-02-08 Micrel �.�.�. ������� ��������� ��������������� ��������� Tele-medicine system
US6698269B2 (en) 2001-04-27 2004-03-02 Oceana Sensor Technologies, Inc. Transducer in-situ testing apparatus and method
US7395214B2 (en) 2001-05-11 2008-07-01 Craig P Shillingburg Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient
US6549796B2 (en) 2001-05-25 2003-04-15 Lifescan, Inc. Monitoring analyte concentration using minimally invasive devices
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7179226B2 (en) 2001-06-21 2007-02-20 Animas Corporation System and method for managing diabetes
EP2319400B1 (en) 2001-06-22 2012-08-22 Nellcor Puritan Bennett Ireland Wavelet-based analysis of pulse oximetry signals
WO2003000127A2 (en) 2001-06-22 2003-01-03 Cygnus, Inc. Method for improving the performance of an analyte monitoring system
US7044911B2 (en) 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
US20030208113A1 (en) 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6754516B2 (en) 2001-07-19 2004-06-22 Nellcor Puritan Bennett Incorporated Nuisance alarm reductions in a physiological monitor
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US20040260478A1 (en) 2001-08-03 2004-12-23 Schwamm Lee H. System, process and diagnostic arrangement establishing and monitoring medication doses for patients
WO2003015629A1 (en) 2001-08-20 2003-02-27 Inverness Medical Limited Wireless diabetes management devices and methods for using the same
DE60238202D1 (en) 2001-08-22 2010-12-16 Instrumentation Lab Co METHOD AND DEVICE FOR CALIBRATING SENSORS
US7096064B2 (en) 2001-08-28 2006-08-22 Medtronic, Inc. Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
JP2003084101A (en) 2001-09-17 2003-03-19 Dainippon Printing Co Ltd Resin composition for optical device, optical device and projection screen
US7052591B2 (en) 2001-09-21 2006-05-30 Therasense, Inc. Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking
US6830562B2 (en) 2001-09-27 2004-12-14 Unomedical A/S Injector device for placing a subcutaneous infusion set
US6731985B2 (en) 2001-10-16 2004-05-04 Pacesetter, Inc. Implantable cardiac stimulation system and method for automatic capture verification calibration
US7854230B2 (en) 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US7204823B2 (en) 2001-12-19 2007-04-17 Medtronic Minimed, Inc. Medication delivery system and monitor
US7729776B2 (en) 2001-12-19 2010-06-01 Cardiac Pacemakers, Inc. Implantable medical device with two or more telemetry systems
US7082334B2 (en) 2001-12-19 2006-07-25 Medtronic, Inc. System and method for transmission of medical and like data from a patient to a dedicated internet website
US20050027182A1 (en) 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US20080255438A1 (en) 2001-12-27 2008-10-16 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7399277B2 (en) 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7022072B2 (en) 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US6980852B2 (en) 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
US6985773B2 (en) 2002-02-07 2006-01-10 Cardiac Pacemakers, Inc. Methods and apparatuses for implantable medical device telemetry power management
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
AU2003213638A1 (en) 2002-02-26 2003-09-09 Sterling Medivations, Inc. Insertion device for an insertion set and method of using the same
US20030212379A1 (en) 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US7043305B2 (en) 2002-03-06 2006-05-09 Cardiac Pacemakers, Inc. Method and apparatus for establishing context among events and optimizing implanted medical device performance
US6998247B2 (en) 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US6936006B2 (en) 2002-03-22 2005-08-30 Novo Nordisk, A/S Atraumatic insertion of a subcutaneous device
GB2388898B (en) 2002-04-02 2005-10-05 Inverness Medical Ltd Integrated sample testing meter
US7410468B2 (en) 2002-04-19 2008-08-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7198606B2 (en) 2002-04-19 2007-04-03 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US7153265B2 (en) 2002-04-22 2006-12-26 Medtronic Minimed, Inc. Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance
EP1498067A1 (en) 2002-04-25 2005-01-19 Matsushita Electric Industrial Co., Ltd. Dosage determination supporting device, injector, and health management supporting system
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US6865407B2 (en) 2002-07-11 2005-03-08 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US20040010207A1 (en) 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
AU2003302720B9 (en) 2002-07-19 2008-08-21 Smiths Detection-Pasadena, Inc. Non-specific sensor array detectors
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
EP1534121B1 (en) 2002-08-13 2014-01-22 University Of Virginia Patent Foundation Method, system, and computer program product for the processing of self-monitoring blood glucose(smbg)data to enhance diabetic self-management
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US7404796B2 (en) 2004-03-01 2008-07-29 Becton Dickinson And Company System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
CN1497256A (en) * 2002-09-19 2004-05-19 王湘生 Non-invasive method for monitoring blood sugar and its device
US7192405B2 (en) 2002-09-30 2007-03-20 Becton, Dickinson And Company Integrated lancet and bodily fluid sensor
KR101226540B1 (en) 2002-10-11 2013-01-25 벡톤 디킨슨 앤드 컴퍼니 System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US7029443B2 (en) 2002-10-21 2006-04-18 Pacesetter, Inc. System and method for monitoring blood glucose levels using an implantable medical device
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US7572237B2 (en) 2002-11-06 2009-08-11 Abbott Diabetes Care Inc. Automatic biological analyte testing meter with integrated lancing device and methods of use
US7009511B2 (en) 2002-12-17 2006-03-07 Cardiac Pacemakers, Inc. Repeater device for communications with an implantable medical device
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7396330B2 (en) 2003-01-07 2008-07-08 Triage Data Networks Wireless, internet-based medical-diagnostic system
US7207947B2 (en) 2003-01-10 2007-04-24 Pacesetter, Inc. System and method for detecting circadian states using an implantable medical device
US20040172307A1 (en) 2003-02-06 2004-09-02 Gruber Martin A. Electronic medical record method
WO2004084820A2 (en) 2003-03-19 2004-10-07 Harry Hebblewhite Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
US20040199056A1 (en) 2003-04-03 2004-10-07 International Business Machines Corporation Body monitoring using local area wireless interfaces
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US7103412B1 (en) 2003-05-02 2006-09-05 Pacesetter, Inc. Implantable cardiac stimulation device and method for detecting asymptomatic diabetes
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US20050016276A1 (en) 2003-06-06 2005-01-27 Palo Alto Sensor Technology Innovation Frequency encoding of resonant mass sensors
US7040139B2 (en) 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US20040254433A1 (en) 2003-06-12 2004-12-16 Bandis Steven D. Sensor introducer system, apparatus and method
US7142911B2 (en) 2003-06-26 2006-11-28 Pacesetter, Inc. Method and apparatus for monitoring drug effects on cardiac electrical signals using an implantable cardiac stimulation device
US7510564B2 (en) 2003-06-27 2009-03-31 Abbott Diabetes Care Inc. Lancing device
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US7424318B2 (en) 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7366556B2 (en) 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1649260A4 (en) 2003-07-25 2010-07-07 Dexcom Inc Electrode systems for electrochemical sensors
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
WO2007120442A2 (en) 2003-07-25 2007-10-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7467003B2 (en) 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20050176136A1 (en) 2003-11-19 2005-08-11 Dexcom, Inc. Afinity domain for analyte sensor
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
WO2005019795A2 (en) 2003-07-25 2005-03-03 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
US7460898B2 (en) 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1652088B1 (en) 2003-07-25 2017-09-13 Philips Intellectual Property & Standards GmbH Method and device for monitoring a system
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8285354B2 (en) 2003-08-01 2012-10-09 Dexcom, Inc. System and methods for processing analyte sensor data
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20070066873A1 (en) 2003-08-22 2007-03-22 Apurv Kamath Systems and methods for processing analyte sensor data
US7203549B2 (en) 2003-10-02 2007-04-10 Medtronic, Inc. Medical device programmer with internal antenna and display
PL1677668T3 (en) 2003-10-13 2010-12-31 Novo Nordisk As Apparatus and method for determining a physiological condition
US7148803B2 (en) 2003-10-24 2006-12-12 Symbol Technologies, Inc. Radio frequency identification (RFID) based sensor networks
US20050090607A1 (en) 2003-10-28 2005-04-28 Dexcom, Inc. Silicone composition for biocompatible membrane
EP1761880B1 (en) 2003-10-29 2013-02-27 Innovision Research & Technology PLC Rfid apparatus
US6928380B2 (en) 2003-10-30 2005-08-09 International Business Machines Corporation Thermal measurements of electronic devices during operation
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US20090012376A1 (en) 2003-11-03 2009-01-08 Children's Medical Center Corporation Continuous Analyte Monitor and Method of Using Same
US7419573B2 (en) 2003-11-06 2008-09-02 3M Innovative Properties Company Circuit for electrochemical sensor strip
US20080197024A1 (en) 2003-12-05 2008-08-21 Dexcom, Inc. Analyte sensor
US8425416B2 (en) 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
ATE480761T1 (en) 2003-12-05 2010-09-15 Dexcom Inc CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8364230B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425417B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US20080200788A1 (en) 2006-10-04 2008-08-21 Dexcorn, Inc. Analyte sensor
ATE474219T1 (en) 2003-12-08 2010-07-15 Dexcom Inc SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYT SENSORS
WO2005057175A2 (en) 2003-12-09 2005-06-23 Dexcom, Inc. Signal processing for continuous analyte sensor
US7076300B1 (en) 2003-12-24 2006-07-11 Pacesetter, Inc. Implantable cardiac stimulation device and method that discriminates between and treats atrial tachycardia and atrial fibrillation
US7384397B2 (en) 2003-12-30 2008-06-10 Medtronic Minimed, Inc. System and method for sensor recalibration
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
US7580812B2 (en) 2004-01-28 2009-08-25 Honeywell International Inc. Trending system and method using window filtering
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
WO2005079257A2 (en) 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
CA2556331A1 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
DE102004011135A1 (en) 2004-03-08 2005-09-29 Disetronic Licensing Ag Method and apparatus for calculating a bolus amount
US7228182B2 (en) 2004-03-15 2007-06-05 Cardiac Pacemakers, Inc. Cryptographic authentication for telemetry with an implantable medical device
JP5051767B2 (en) 2004-03-22 2012-10-17 ボディーメディア インコーポレイテッド Device for monitoring human condition parameters
JP2007535974A (en) 2004-03-26 2007-12-13 ノボ・ノルデイスク・エー/エス Display device for related data of diabetic patients
US6971274B2 (en) 2004-04-02 2005-12-06 Sierra Instruments, Inc. Immersible thermal mass flow meter
WO2005106017A2 (en) 2004-04-21 2005-11-10 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US20050245799A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US7241266B2 (en) 2004-05-20 2007-07-10 Digital Angel Corporation Transducer for embedded bio-sensor using body energy as a power source
US7118667B2 (en) 2004-06-02 2006-10-10 Jin Po Lee Biosensors having improved sample application and uses thereof
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
US7565197B2 (en) 2004-06-18 2009-07-21 Medtronic, Inc. Conditional requirements for remote medical device programming
US7623988B2 (en) 2004-06-23 2009-11-24 Cybiocare Inc. Method and apparatus for the monitoring of clinical states
US7233822B2 (en) 2004-06-29 2007-06-19 Medtronic, Inc. Combination of electrogram and intra-cardiac pressure to discriminate between fibrillation and tachycardia
US20060001538A1 (en) 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20060015020A1 (en) 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US20080242961A1 (en) 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US20060020192A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7344500B2 (en) 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US8313433B2 (en) 2004-08-06 2012-11-20 Medtronic Minimed, Inc. Medical data management system and process
WO2006026741A1 (en) 2004-08-31 2006-03-09 Lifescan Scotland Limited Wearable sensor device and system
WO2006029090A2 (en) 2004-09-02 2006-03-16 Proteus Biomedical, Inc. Methods and apparatus for tissue activation and monitoring
JP2008511373A (en) 2004-09-03 2008-04-17 ノボ・ノルデイスク・エー/エス Method for calibrating a system for measuring the concentration of a body substance and apparatus for carrying out the method
EP1845845B1 (en) 2004-11-02 2010-09-01 Medtronic, Inc. Techniques for user-activated data retention in an implantable medical device
US7237712B2 (en) 2004-12-01 2007-07-03 Alfred E. Mann Foundation For Scientific Research Implantable device and communication integrated circuit implementable therein
JPWO2006070827A1 (en) 2004-12-28 2008-06-12 新世代株式会社 Health care support system and recording medium
US20090082693A1 (en) 2004-12-29 2009-03-26 Therasense, Inc. Method and apparatus for providing temperature sensor module in a data communication system
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US20070027381A1 (en) 2005-07-29 2007-02-01 Therasense, Inc. Inserter and methods of use
US20060166629A1 (en) 2005-01-24 2006-07-27 Therasense, Inc. Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems
US7502644B2 (en) 2005-01-25 2009-03-10 Pacesetter, Inc. System and method for distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device
US20060173260A1 (en) 2005-01-31 2006-08-03 Gmms Ltd System, device and method for diabetes treatment and monitoring
US7547281B2 (en) 2005-02-01 2009-06-16 Medtronic Minimed, Inc. Algorithm sensor augmented bolus estimator for semi-closed loop infusion system
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US20070071681A1 (en) 2005-03-15 2007-03-29 Entelos, Inc. Apparatus and method for computer modeling type 1 diabetes
US7889069B2 (en) 2005-04-01 2011-02-15 Codman & Shurtleff, Inc. Wireless patient monitoring system
WO2006110193A2 (en) 2005-04-08 2006-10-19 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US7270633B1 (en) 2005-04-22 2007-09-18 Cardiac Pacemakers, Inc. Ambulatory repeater for use in automated patient care and method thereof
DE102005019306B4 (en) 2005-04-26 2011-09-01 Disetronic Licensing Ag Energy-optimized data transmission of a medical device
US7590443B2 (en) 2005-04-27 2009-09-15 Pacesetter, Inc System and method for detecting hypoglycemia based on a paced depolarization integral using an implantable medical device
US8700157B2 (en) 2005-04-29 2014-04-15 Medtronic, Inc. Telemetry head programmer for implantable medical device and system and method
US20060247985A1 (en) 2005-04-29 2006-11-02 Therasense, Inc. Method and system for monitoring consumable item usage and providing replenishment thereof
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US20060264783A1 (en) 2005-05-09 2006-11-23 Holmes Elizabeth A Systems and methods for monitoring pharmacological parameters
US7604178B2 (en) 2005-05-11 2009-10-20 Intelleflex Corporation Smart tag activation
CA2612714C (en) 2005-05-13 2013-09-24 Trustees Of Boston University Fully automated control system for type 1 diabetes
US7541935B2 (en) 2005-05-19 2009-06-02 Proacticare Llc System and methods for monitoring caregiver performance
JP2008542764A (en) 2005-06-02 2008-11-27 アイセンス コーポレーション Filtering and use of multiple data points in analyte sensors
US20060272652A1 (en) 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
US20070033074A1 (en) 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system
US20070016449A1 (en) 2005-06-29 2007-01-18 Gary Cohen Flexible glucose analysis using varying time report deltas and configurable glucose target ranges
KR101136889B1 (en) 2005-07-12 2012-04-20 메사추세츠 인스티튜트 오브 테크놀로지 Wireless non-radiative energy transfer
EP1758039A1 (en) 2005-08-27 2007-02-28 Roche Diagnostics GmbH Communication adaptor for portable medical or therapeutical devices
ES2575660T3 (en) 2005-09-09 2016-06-30 F. Hoffmann-La Roche Ag System, tools, devices and program for diabetic care
US8298389B2 (en) 2005-09-12 2012-10-30 Abbott Diabetes Care Inc. In vitro analyte sensor, and methods
US9072476B2 (en) 2005-09-23 2015-07-07 Medtronic Minimed, Inc. Flexible sensor apparatus
US7725148B2 (en) 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US7846311B2 (en) 2005-09-27 2010-12-07 Abbott Diabetes Care Inc. In vitro analyte sensor and methods of use
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US20070095661A1 (en) 2005-10-31 2007-05-03 Yi Wang Method of making, and, analyte sensor
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
EP3064236B1 (en) 2005-11-08 2020-02-05 Bigfoot Biomedical, Inc. Method and system for manual and autonomous control of an infusion pump
US20070173706A1 (en) 2005-11-11 2007-07-26 Isense Corporation Method and apparatus for insertion of a sensor
US7918975B2 (en) 2005-11-17 2011-04-05 Abbott Diabetes Care Inc. Analytical sensors for biological fluid
WO2007062173A1 (en) 2005-11-22 2007-05-31 Vocollect Healthcare Systems, Inc. Advanced diabetes management system (adms)
US7941200B2 (en) 2005-12-08 2011-05-10 Roche Diagnostics Operations, Inc. System and method for determining drug administration information
CA2636034A1 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care Inc. Medical device insertion
US8515518B2 (en) 2005-12-28 2013-08-20 Abbott Diabetes Care Inc. Analyte monitoring
US8160670B2 (en) 2005-12-28 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
EP2004796B1 (en) 2006-01-18 2015-04-08 DexCom, Inc. Membranes for an analyte sensor
US7574266B2 (en) 2006-01-19 2009-08-11 Medtronic, Inc. System and method for telemetry with an implantable medical device
US20070179349A1 (en) 2006-01-19 2007-08-02 Hoyme Kenneth P System and method for providing goal-oriented patient management based upon comparative population data analysis
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
EP3649925A1 (en) 2006-02-22 2020-05-13 DexCom, Inc. Analyte sensor
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US7359837B2 (en) 2006-04-27 2008-04-15 Medtronic, Inc. Peak data retention of signal data in an implantable medical device
US20070258395A1 (en) 2006-04-28 2007-11-08 Medtronic Minimed, Inc. Wireless data communication protocols for a medical device network
US8380300B2 (en) 2006-04-28 2013-02-19 Medtronic, Inc. Efficacy visualization
US20070253021A1 (en) 2006-04-28 2007-11-01 Medtronic Minimed, Inc. Identification of devices in a medical device network and wireless data communication techniques utilizing device identifiers
GB0608829D0 (en) 2006-05-04 2006-06-14 Husheer Shamus L G In-situ measurement of physical parameters
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US7796038B2 (en) 2006-06-12 2010-09-14 Intelleflex Corporation RFID sensor tag with manual modes and functions
US20080177149A1 (en) 2006-06-16 2008-07-24 Stefan Weinert System and method for collecting patient information from which diabetes therapy may be determined
US20070299617A1 (en) 2006-06-27 2007-12-27 Willis John P Biofouling self-compensating biosensor
US20090105560A1 (en) 2006-06-28 2009-04-23 David Solomon Lifestyle and eating advisor based on physiological and biological rhythm monitoring
US7866026B1 (en) 2006-08-01 2011-01-11 Abbott Diabetes Care Inc. Method for making calibration-adjusted sensors
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
US9056165B2 (en) 2006-09-06 2015-06-16 Medtronic Minimed, Inc. Intelligent therapy recommendation algorithm and method of using the same
US20080071328A1 (en) 2006-09-06 2008-03-20 Medtronic, Inc. Initiating medical system communications
US7779332B2 (en) 2006-09-25 2010-08-17 Alfred E. Mann Foundation For Scientific Research Rotationally invariant non-coherent burst coding
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8449464B2 (en) 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8478377B2 (en) 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US8562528B2 (en) 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US8275438B2 (en) 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
AU2007308804A1 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care, Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
EP1918837A1 (en) 2006-10-31 2008-05-07 F. Hoffmann-La Roche AG Method for processing a chronological sequence of measurements of a time dependent parameter
US20080119705A1 (en) 2006-11-17 2008-05-22 Medtronic Minimed, Inc. Systems and Methods for Diabetes Management Using Consumer Electronic Devices
US20080139910A1 (en) 2006-12-06 2008-06-12 Metronic Minimed, Inc. Analyte sensor and method of using the same
US20080154513A1 (en) 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US7999674B2 (en) 2007-01-15 2011-08-16 Deka Products Limited Partnership Device and method for food management
US10154804B2 (en) 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US7659823B1 (en) 2007-03-20 2010-02-09 At&T Intellectual Property Ii, L.P. Tracking variable conditions using radio frequency identification
US20080234943A1 (en) 2007-03-20 2008-09-25 Pinaki Ray Computer program for diabetes management
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683930A1 (en) 2007-04-14 2008-10-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2009096992A1 (en) 2007-04-14 2009-08-06 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CN101715555A (en) 2007-04-27 2010-05-26 艾伯特糖尿病护理公司 Test strip identification using conductive patterns
US20080312845A1 (en) 2007-05-14 2008-12-18 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
EP2156684A4 (en) 2007-05-14 2012-10-24 Abbott Diabetes Care Inc Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20080300572A1 (en) 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
WO2008154312A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20080312518A1 (en) 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
EP2166929B1 (en) 2007-06-15 2012-12-19 F. Hoffmann-La Roche AG Visualization of a parameter which is measured on the human body
EP2170158B1 (en) 2007-06-27 2017-07-05 F. Hoffmann-La Roche AG Patient information input interface for a therapy system
EP2562664B1 (en) 2007-06-27 2020-11-25 Roche Diabetes Care GmbH System for determining an insulin delivery and communicating a dose in automated pancreas software
EP2170159B8 (en) 2007-06-29 2016-09-21 Roche Diabetes Care GmbH Combination communication device and medical device for communicating wirelessly with a remote medical device
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20090036760A1 (en) 2007-07-31 2009-02-05 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US7731658B2 (en) 2007-08-16 2010-06-08 Cardiac Pacemakers, Inc. Glycemic control monitoring using implantable medical device
US9968742B2 (en) 2007-08-29 2018-05-15 Medtronic Minimed, Inc. Combined sensor and infusion set using separated sites
US20090063402A1 (en) 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
DE102007047351A1 (en) 2007-10-02 2009-04-09 B. Braun Melsungen Ag System and method for monitoring and controlling blood glucose levels
US20090085768A1 (en) 2007-10-02 2009-04-02 Medtronic Minimed, Inc. Glucose sensor transceiver
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US7783442B2 (en) 2007-10-31 2010-08-24 Medtronic Minimed, Inc. System and methods for calibrating physiological characteristic sensors
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US20090164190A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Physiological condition simulation device and method
DE102008008072A1 (en) 2008-01-29 2009-07-30 Balluff Gmbh sensor
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
CA2715624A1 (en) 2008-02-20 2009-08-27 Dexcom, Inc. Continuous medicament sensor system for in vivo use
EP2252196A4 (en) 2008-02-21 2013-05-15 Dexcom Inc Systems and methods for processing, transmitting and displaying sensor data
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US20090242399A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090247855A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
NO2260423T3 (en) 2008-04-04 2018-07-28
US20090267765A1 (en) 2008-04-29 2009-10-29 Jack Greene Rfid to prevent reprocessing
US7938797B2 (en) 2008-05-05 2011-05-10 Asante Solutions, Inc. Infusion pump system
CA2724446C (en) 2008-05-14 2017-04-04 Espenusa Holding, Llc Physical activity monitor and data collection unit
WO2009143289A2 (en) 2008-05-20 2009-11-26 Deka Products Limited Partnership Rfid system
US8432070B2 (en) 2008-08-25 2013-04-30 Qualcomm Incorporated Passive receivers for wireless power transmission
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
WO2010030609A1 (en) 2008-09-09 2010-03-18 Vivomedical, Inc. Sweat collection devices for glucose measurement
US9320470B2 (en) 2008-12-31 2016-04-26 Medtronic Minimed, Inc. Method and/or system for sensor artifact filtering
US8974439B2 (en) 2009-01-02 2015-03-10 Asante Solutions, Inc. Infusion pump system and methods
EP2413781B1 (en) 2009-03-31 2019-07-24 Abbott Diabetes Care Inc. Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model
US9792408B2 (en) 2009-07-02 2017-10-17 Covidien Lp Method and apparatus to detect transponder tagged objects and to communicate with medical telemetry devices, for example during medical procedures
EP3970610A3 (en) 2009-07-02 2022-05-18 Dexcom, Inc. Analyte sensors and methods of manufacturing same
US20120165626A1 (en) 2009-07-13 2012-06-28 Irina Finkelshtein V Devices, methods, and kits for determining analyte concentrations
US9357951B2 (en) 2009-09-30 2016-06-07 Dexcom, Inc. Transcutaneous analyte sensor
US9949672B2 (en) 2009-12-17 2018-04-24 Ascensia Diabetes Care Holdings Ag Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels
US8579879B2 (en) 2010-02-19 2013-11-12 Medtronic Minimed, Inc. Closed-loop glucose control startup
US20110208027A1 (en) 2010-02-23 2011-08-25 Roche Diagnostics Operations, Inc. Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes
US9336353B2 (en) 2010-06-25 2016-05-10 Dexcom, Inc. Systems and methods for communicating sensor data between communication devices of a glucose monitoring system
EP2621339B1 (en) 2010-09-29 2020-01-15 Dexcom, Inc. Advanced continuous analyte monitoring system
US9241631B2 (en) 2010-10-27 2016-01-26 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode
US20120165640A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Operations, Inc. Structured blood glucose testing performed on handheld diabetes management devices
WO2013022775A1 (en) 2011-08-05 2013-02-14 Dexcom, Inc. Systems and methods for detecting glucose level data patterns

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462048A (en) * 1982-02-11 1984-07-24 Rca Corporation Noise reduction circuitry for audio signals
US5568400A (en) * 1989-09-01 1996-10-22 Stark; Edward W. Multiplicative signal correction method and apparatus
US5660163A (en) * 1993-11-19 1997-08-26 Alfred E. Mann Foundation For Scientific Research Glucose sensor assembly
US6143164A (en) * 1997-02-06 2000-11-07 E. Heller & Company Small volume in vitro analyte sensor
US6424847B1 (en) * 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US7317938B2 (en) * 1999-10-08 2008-01-08 Sensys Medical, Inc. Method of adapting in-vitro models to aid in noninvasive glucose determination
US6676816B2 (en) * 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
US20040099529A1 (en) * 2001-05-11 2004-05-27 Fei Mao Transition metal complexes with (pyridyl)imidazole ligands
US20030042137A1 (en) * 2001-05-15 2003-03-06 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US20030191377A1 (en) * 2002-04-04 2003-10-09 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US20070118405A1 (en) * 2003-04-18 2007-05-24 Insulet Corporation User Interface For Infusion Pump Remote Controller And Method Of Using The Same
US7258673B2 (en) * 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US20050027181A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US7699964B2 (en) * 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US20070060803A1 (en) * 2004-02-26 2007-03-15 Liljeryd Lars G Metabolic Monitoring, a Method and Apparatus for Indicating a Health-Related condition of a Subject
US7499002B2 (en) * 2005-02-08 2009-03-03 International Business Machines Corporation Retractable string interface for stationary and portable devices
US20070213657A1 (en) * 2006-02-28 2007-09-13 Abbott Diabetes Care, Inc Smart messages and alerts for an infusion delivery and management system
US20080319279A1 (en) * 2007-06-21 2008-12-25 Immersion Corporation Haptic Health Feedback Monitoring

Cited By (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11627900B2 (en) 2003-12-05 2023-04-18 Dexcom, Inc. Analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US8390455B2 (en) 2005-02-08 2013-03-05 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8358210B2 (en) 2005-02-08 2013-01-22 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8115635B2 (en) 2005-02-08 2012-02-14 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8542122B2 (en) 2005-02-08 2013-09-24 Abbott Diabetes Care Inc. Glucose measurement device and methods using RFID
US8223021B2 (en) 2005-02-08 2012-07-17 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9031630B2 (en) 2006-02-28 2015-05-12 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US8506482B2 (en) 2006-02-28 2013-08-13 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9844329B2 (en) 2006-02-28 2017-12-19 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US11872039B2 (en) 2006-02-28 2024-01-16 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9743863B2 (en) 2006-03-31 2017-08-29 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8933664B2 (en) 2006-03-31 2015-01-13 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8593109B2 (en) 2006-03-31 2013-11-26 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9380971B2 (en) 2006-03-31 2016-07-05 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US10278630B2 (en) 2006-08-09 2019-05-07 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US11864894B2 (en) 2006-08-09 2024-01-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9833181B2 (en) 2006-08-09 2017-12-05 Abbot Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8515517B2 (en) 2006-10-02 2013-08-20 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9629578B2 (en) 2006-10-02 2017-04-25 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9839383B2 (en) 2006-10-02 2017-12-12 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US10342469B2 (en) 2006-10-02 2019-07-09 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9357959B2 (en) 2006-10-02 2016-06-07 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9113828B2 (en) 2006-10-25 2015-08-25 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9814428B2 (en) 2006-10-25 2017-11-14 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8216137B2 (en) 2006-10-25 2012-07-10 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US10194868B2 (en) 2006-10-25 2019-02-05 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US11282603B2 (en) 2006-10-25 2022-03-22 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8718958B2 (en) 2006-10-26 2014-05-06 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US9882660B2 (en) 2006-10-26 2018-01-30 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US10903914B2 (en) 2006-10-26 2021-01-26 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US11722229B2 (en) 2006-10-26 2023-08-08 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US11039767B2 (en) 2007-04-14 2021-06-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10349877B2 (en) 2007-04-14 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9060719B2 (en) 2007-05-14 2015-06-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10045720B2 (en) 2007-05-14 2018-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9801571B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10634662B2 (en) 2007-05-14 2020-04-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8484005B2 (en) 2007-05-14 2013-07-09 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9797880B2 (en) 2007-05-14 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10653344B2 (en) 2007-05-14 2020-05-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11828748B2 (en) 2007-05-14 2023-11-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9737249B2 (en) 2007-05-14 2017-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10119956B2 (en) 2007-05-14 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10463310B2 (en) 2007-05-14 2019-11-05 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10820841B2 (en) 2007-05-14 2020-11-03 Abbot Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10991456B2 (en) 2007-05-14 2021-04-27 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10031002B2 (en) 2007-05-14 2018-07-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11300561B2 (en) 2007-05-14 2022-04-12 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US9804150B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9558325B2 (en) 2007-05-14 2017-01-31 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8682615B2 (en) 2007-05-14 2014-03-25 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10261069B2 (en) 2007-05-14 2019-04-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10976304B2 (en) 2007-05-14 2021-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11125592B2 (en) 2007-05-14 2021-09-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11119090B2 (en) 2007-05-14 2021-09-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10143409B2 (en) 2007-05-14 2018-12-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11076785B2 (en) 2007-05-14 2021-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8612163B2 (en) 2007-05-14 2013-12-17 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9675289B2 (en) * 2007-06-18 2017-06-13 Roche Diabetes Care, Inc. Method and glucose monitoring system for monitoring individual metabolic response and for generating nutritional feedback
US20110053121A1 (en) * 2007-06-18 2011-03-03 Roche Diagnostics International Ag Method and glucose monitoring system for monitoring individual metabolic response and for generating nutritional feedback
US11678821B2 (en) 2007-06-29 2023-06-20 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US9913600B2 (en) 2007-06-29 2018-03-13 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US10856785B2 (en) 2007-06-29 2020-12-08 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US20220273203A1 (en) * 2007-07-31 2022-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9398872B2 (en) 2007-07-31 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US11083843B2 (en) 2007-10-23 2021-08-10 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US9804148B2 (en) 2007-10-23 2017-10-31 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US10173007B2 (en) 2007-10-23 2019-01-08 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US9439586B2 (en) 2007-10-23 2016-09-13 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9332934B2 (en) 2007-10-23 2016-05-10 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US9743865B2 (en) 2007-10-23 2017-08-29 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US10685749B2 (en) 2007-12-19 2020-06-16 Abbott Diabetes Care Inc. Insulin delivery apparatuses capable of bluetooth data transmission
US9320468B2 (en) 2008-01-31 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9770211B2 (en) 2008-01-31 2017-09-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9320462B2 (en) 2008-03-28 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor calibration management
US11779248B2 (en) 2008-03-28 2023-10-10 Abbott Diabetes Care Inc. Analyte sensor calibration management
US10463288B2 (en) 2008-03-28 2019-11-05 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9730623B2 (en) 2008-03-28 2017-08-15 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8718739B2 (en) 2008-03-28 2014-05-06 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9831985B2 (en) 2008-05-30 2017-11-28 Abbott Diabetes Care Inc. Close proximity communication device and methods
US9931075B2 (en) 2008-05-30 2018-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10327682B2 (en) 2008-05-30 2019-06-25 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8737259B2 (en) 2008-05-30 2014-05-27 Abbott Diabetes Care Inc. Close proximity communication device and methods
US11735295B2 (en) 2008-05-30 2023-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9184875B2 (en) 2008-05-30 2015-11-10 Abbott Diabetes Care, Inc. Close proximity communication device and methods
US11770210B2 (en) 2008-05-30 2023-09-26 Abbott Diabetes Care Inc. Close proximity communication device and methods
US9541556B2 (en) 2008-05-30 2017-01-10 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US9795328B2 (en) 2008-05-30 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US10328201B2 (en) 2008-07-14 2019-06-25 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US11621073B2 (en) 2008-07-14 2023-04-04 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US9572934B2 (en) 2008-08-31 2017-02-21 Abbott DiabetesCare Inc. Robust closed loop control and methods
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
US10188794B2 (en) 2008-08-31 2019-01-29 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9610046B2 (en) 2008-08-31 2017-04-04 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US11679200B2 (en) 2008-08-31 2023-06-20 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9662056B2 (en) 2008-09-30 2017-05-30 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11484234B2 (en) 2008-09-30 2022-11-01 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11464434B2 (en) 2008-09-30 2022-10-11 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US11013439B2 (en) 2008-09-30 2021-05-25 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11202592B2 (en) 2008-09-30 2021-12-21 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8744547B2 (en) 2008-09-30 2014-06-03 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US10045739B2 (en) 2008-09-30 2018-08-14 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US11272890B2 (en) 2008-11-10 2022-03-15 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US11678848B2 (en) 2008-11-10 2023-06-20 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9730650B2 (en) 2008-11-10 2017-08-15 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US10089446B2 (en) 2009-01-29 2018-10-02 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US9066709B2 (en) 2009-01-29 2015-06-30 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8676513B2 (en) 2009-01-29 2014-03-18 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US11464430B2 (en) 2009-01-29 2022-10-11 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8532935B2 (en) 2009-01-29 2013-09-10 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US10009244B2 (en) 2009-04-15 2018-06-26 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US9178752B2 (en) 2009-04-15 2015-11-03 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8730058B2 (en) 2009-04-15 2014-05-20 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US20120029942A1 (en) * 2009-04-17 2012-02-02 Arkray, Inc. User-Specific Data Provision System, User-Specific Data Provision Method, Server Device, and Handheld Device
US9949639B2 (en) 2009-04-29 2018-04-24 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US10617296B2 (en) 2009-04-29 2020-04-14 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US9693688B2 (en) 2009-04-29 2017-07-04 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US9310230B2 (en) 2009-04-29 2016-04-12 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US10172518B2 (en) 2009-04-29 2019-01-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US9088452B2 (en) 2009-04-29 2015-07-21 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US10420489B2 (en) 2009-05-29 2019-09-24 University Of Virginia Patent Foundation System coordinator and modular architecture for open-loop and closed-loop control of diabetes
US9795326B2 (en) 2009-07-23 2017-10-24 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US10872102B2 (en) 2009-07-23 2020-12-22 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US10827954B2 (en) 2009-07-23 2020-11-10 Abbott Diabetes Care Inc. Continuous analyte measurement systems and systems and methods for implanting them
US10660554B2 (en) 2009-07-31 2020-05-26 Abbott Diabetes Care Inc. Methods and devices for analyte monitoring calibration
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US11234625B2 (en) 2009-07-31 2022-02-01 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US8718965B2 (en) 2009-07-31 2014-05-06 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US9936910B2 (en) 2009-07-31 2018-04-10 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US9549694B2 (en) 2009-08-31 2017-01-24 Abbott Diabetes Care Inc. Displays for a medical device
US10772572B2 (en) 2009-08-31 2020-09-15 Abbott Diabetes Care Inc. Displays for a medical device
US9186113B2 (en) 2009-08-31 2015-11-17 Abbott Diabetes Care Inc. Displays for a medical device
US10456091B2 (en) 2009-08-31 2019-10-29 Abbott Diabetes Care Inc. Displays for a medical device
US8816862B2 (en) 2009-08-31 2014-08-26 Abbott Diabetes Care Inc. Displays for a medical device
US11241175B2 (en) 2009-08-31 2022-02-08 Abbott Diabetes Care Inc. Displays for a medical device
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US10881355B2 (en) 2009-08-31 2021-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US11202586B2 (en) 2009-08-31 2021-12-21 Abbott Diabetes Care Inc. Displays for a medical device
US9226714B2 (en) 2009-08-31 2016-01-05 Abbott Diabetes Care Inc. Displays for a medical device
USRE47315E1 (en) 2009-08-31 2019-03-26 Abbott Diabetes Care Inc. Displays for a medical device
US11730429B2 (en) 2009-08-31 2023-08-22 Abbott Diabetes Care Inc. Displays for a medical device
US10918342B1 (en) 2009-08-31 2021-02-16 Abbott Diabetes Care Inc. Displays for a medical device
US10123752B2 (en) 2009-08-31 2018-11-13 Abbott Diabetes Care Inc. Displays for a medical device
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9750439B2 (en) 2009-09-29 2017-09-05 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US10349874B2 (en) 2009-09-29 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US10117606B2 (en) 2009-10-30 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US11207005B2 (en) 2009-10-30 2021-12-28 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US9050041B2 (en) 2009-10-30 2015-06-09 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US11069434B2 (en) 2010-03-11 2021-07-20 University Of Virginia Patent Foundation Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
WO2011112974A1 (en) * 2010-03-11 2011-09-15 University Of Virginia Patent Foundation Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
US9398869B2 (en) 2010-03-26 2016-07-26 University Of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
WO2011119832A1 (en) * 2010-03-26 2011-09-29 University Of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
EP2552301A4 (en) * 2010-03-26 2014-07-30 Univ Virginia Patent Found Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
EP3841968A1 (en) 2010-03-26 2021-06-30 The University of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
EP2552301A1 (en) * 2010-03-26 2013-02-06 University Of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
EP3593711A1 (en) 2010-03-26 2020-01-15 The University of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
EP4183326A1 (en) 2010-03-26 2023-05-24 University Of Virginia Patent Foundation Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US11478173B2 (en) 2010-06-29 2022-10-25 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US10722162B2 (en) 2011-04-15 2020-07-28 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10682084B2 (en) 2011-04-15 2020-06-16 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10561354B2 (en) 2011-04-15 2020-02-18 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10835162B2 (en) 2011-04-15 2020-11-17 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10610141B2 (en) 2011-04-15 2020-04-07 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10624568B2 (en) 2011-04-15 2020-04-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
WO2012155032A3 (en) * 2011-05-11 2013-01-10 Bayer Healthcare Llc Back calibration of sensor data
EP3799073A1 (en) 2011-08-26 2021-03-31 The University of Virginia Patent Foundation Method, system and computer readable medium for adaptive advisory control of diabetes
US11406331B2 (en) 2011-10-31 2022-08-09 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9913619B2 (en) 2011-10-31 2018-03-13 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9289179B2 (en) 2011-11-23 2016-03-22 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10939859B2 (en) 2011-11-23 2021-03-09 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9743872B2 (en) 2011-11-23 2017-08-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10136847B2 (en) 2011-11-23 2018-11-27 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US11391723B2 (en) 2011-11-25 2022-07-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US10345291B2 (en) 2012-08-30 2019-07-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10942164B2 (en) 2012-08-30 2021-03-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10656139B2 (en) 2012-08-30 2020-05-19 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10842420B2 (en) 2012-09-26 2020-11-24 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9655565B2 (en) 2012-10-30 2017-05-23 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US10555705B2 (en) 2012-10-30 2020-02-11 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US9119528B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for providing sensitive and specific alarms
US11690577B2 (en) 2012-10-30 2023-07-04 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US10188334B2 (en) 2012-10-30 2019-01-29 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9801577B2 (en) 2012-10-30 2017-10-31 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US10702215B2 (en) 2012-10-30 2020-07-07 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US9119529B2 (en) 2012-10-30 2015-09-01 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11006903B2 (en) 2012-10-30 2021-05-18 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US10143426B2 (en) 2012-10-30 2018-12-04 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US11026640B1 (en) 2012-10-30 2021-06-08 Dexcom, Inc. Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
WO2014128638A1 (en) 2013-02-20 2014-08-28 Università Degli Studi Di Padova Area Trasfermiento Di Tecnologia Retrospective retrofitting method to generate a continuous glucose concentration profile
EP3662833A1 (en) 2013-02-20 2020-06-10 Dexcom, Inc. Retrospective retrofitting method to generate a continuous glucose concentration profile
US11633156B2 (en) 2013-02-20 2023-04-25 Dexcom Inc. Retrospective retrofitting method to generate a continuous glucose concentration profile by exploiting continuous glucose monitoring sensor data and blood glucose measurements
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10874336B2 (en) 2013-03-15 2020-12-29 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
EP3068290B1 (en) * 2013-11-14 2020-08-26 The Regents of The University of California Glucose rate increase detector: a meal detection module for the health monitoring system
US11229382B2 (en) 2013-12-31 2022-01-25 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US10881334B2 (en) 2014-08-14 2021-01-05 University Of Virginia Patent Foundation Accuracy continuous glucose monitoring method, system, and device
WO2016025874A1 (en) 2014-08-14 2016-02-18 University Of Virginia Patent Foundation Improved accuracy continuous glucose monitoring method, system, and device
US11311665B2 (en) 2015-06-09 2022-04-26 University Of Virginia Patent Foundation Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
WO2018074894A1 (en) * 2016-10-20 2018-04-26 삼성전자 주식회사 Electronic device and method for controlling same
US11324458B2 (en) 2016-10-20 2022-05-10 Samsung Electronics Co., Ltd. Electronic device and method for controlling same
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11259726B2 (en) 2017-09-26 2022-03-01 Senseonics, Incorporated Methods and systems for weighting calibration points and updating lag parameters
US11185264B2 (en) * 2017-09-26 2021-11-30 Senseonics, Incorporated Methods and systems for weighting calibration points and updating lag parameters
US11672450B2 (en) 2017-09-26 2023-06-13 Senseonics, Incorporated Methods and systems for weighting calibration points and updating lag parameters
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors

Also Published As

Publication number Publication date
JP2009507224A (en) 2009-02-19
US20160007890A1 (en) 2016-01-14
CN101365374B (en) 2011-11-16
JP2012210431A (en) 2012-11-01
EP1921980A4 (en) 2010-03-10
US10194850B2 (en) 2019-02-05
CN102440785A (en) 2012-05-09
CN101365374A (en) 2009-02-11
WO2007027691A1 (en) 2007-03-08
EP1921980A1 (en) 2008-05-21
CA2620586A1 (en) 2007-03-08
US20190343433A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
US20190343433A1 (en) Accuracy of continuous glucose sensors
Steil et al. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor
US20190019571A1 (en) Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data
Guerra et al. Enhancing the accuracy of subcutaneous glucose sensors: a real-time deconvolution-based approach
Holzinger et al. Impact of shock requiring norepinephrine on the accuracy and reliability of subcutaneous continuous glucose monitoring
Caduff et al. Non-invasive glucose monitoring in patients with Type 1 diabetes: A Multisensor system combining sensors for dielectric and optical characterisation of skin
Del Favero et al. Improving accuracy and precision of glucose sensor profiles: retrospective fitting by constrained deconvolution
US9854998B2 (en) Method and/or system for multicompartment analyte monitoring
EP2129277A2 (en) Basal rate testing using blood glucose input
Acciaroli et al. Reduction of blood glucose measurements to calibrate subcutaneous glucose sensors: A bayesian multiday framework
Keenan et al. Interstitial fluid glucose time-lag correction for real-time continuous glucose monitoring
US20230039204A1 (en) Method for calculating calibration sensitivity of sensor for insertion into body
Kovatchev et al. Peculiarities of the continuous glucose monitoring data stream and their impact on developing closed-loop control technology
Vettoretti et al. Modeling the error of factory-calibrated continuous glucose monitoring sensors: application to Dexcom G6 sensor data
Block et al. Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects
Reiterer et al. Identification of CGM time delays and implications for BG control in T1DM
DK1793321T3 (en) Evaluation method and analysis system of an analyte in the body fluid of a human or animal
Sato et al. Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
Van Herpe et al. The application of model predictive control to normalize glycemia of critically ill patients
Laguna et al. Postprandial performance of Dexcom® SEVEN® PLUS and Medtronic® Paradigm® Veo™: modeling and statistical analysis
Al Ahdab et al. State space temporal gaussian processes for glucose measurements
Del Favero et al. Retrofitting CGM traces
Baines et al. Comparison of venous, capillary and interstitial blood glucose data measured during hyperbaric oxygen treatment from patients with diabetes mellitus
King et al. Mathematical Models of the Metabolic System in Health and in Diabetes: Modeling of Calibration Effectiveness and Blood-to-Interstitial Glucose Dynamics as Potential Confounders of the Accuracy of Continuous Glucose Sensors during Hyperinsulinemic Clamp
Fabris et al. Modeling the CGM measurement error

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF VIRGINIA, VIRGINIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KING, CHRISTOPHER RYAN;KOVATCHEV, BORIS P.;REEL/FRAME:021955/0662;SIGNING DATES FROM 20081113 TO 20081117

AS Assignment

Owner name: ABBOTT DIABETES CARE, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF VIRGINIA PATENT FOUNDATION;REEL/FRAME:022174/0021

Effective date: 20090129

Owner name: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, VIRGINIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF VIRGINIA;REEL/FRAME:022173/0825

Effective date: 20081118

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF VIRGINIA PATENT FOUNDATION;REEL/FRAME:023629/0099

Effective date: 20090319

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION